[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 172
6. Fu K, Meng ZB, Li J, Li HC: [Repairing the defect of benign bone tumor with the coralline hydroxyapatite]. Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2008 May;33(5):421-4
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Repairing the defect of benign bone tumor with the coralline hydroxyapatite].
  • OBJECTIVE: To observe the clinical effect of repairing bone defectin post-operation benign tumor with coralline hydroxyapatite(CHAP).
  • The CHAP was implanted into the lesion after bone tumor curettage to 25 patients.
  • The sizes of bone defect ranged from 0.8 cm x 0.5 cm x 0.5 cm to 10 cm x 3.5 cm x 2 cm.
  • X-ray showed that there was osteogenesis at the cortical bone 1 month post-operation.
  • There is corresponding synchronization between bone formation with CHAP biodegradation.
  • The CHAP is an excellent bone defect repairing material.
  • [MeSH-major] Bone Neoplasms / surgery. Ceramics. Giant Cell Tumor of Bone / surgery. Hydroxyapatites. Prostheses and Implants
  • [MeSH-minor] Adolescent. Adult. Aged. Bone Cysts / surgery. Bone Regeneration. Bone Substitutes. Child. Female. Femur / surgery. Humans. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18544846.001).
  • [ISSN] 1672-7347
  • [Journal-full-title] Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
  • [ISO-abbreviation] Zhong Nan Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Bone Substitutes; 0 / Hydroxyapatites; 0 / coralline hydroxyapatite
  •  go-up   go-down


7. Meyer A, Bastian L, Bruns F: Benign giant cell tumor of the spine: an unusual indication for radiotherapy. Arch Orthop Trauma Surg; 2006 Oct;126(8):517-21

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign giant cell tumor of the spine: an unusual indication for radiotherapy.
  • INTRODUCTION: Giant cell tumors are rare primary bone tumors.
  • CASE REPORT: We report about a 64-year-old female patient presenting with history of three osseous and one pulmonal manifestation of a benign giant cell tumor that have manifested metachronously within 23 years.
  • The two periphery bone and the one pulmonal manifestation were treated surgically with success.
  • Nine months later, local recurrence of this benign giant cell tumor developed at the thoracic spine and was treated with radiotherapy with a total dose of 45 Gy.
  • Due to neurological deficits a laminectomy and a stabilization of the destroyed sixth vertebra with bone cement was carried out.
  • Histopathological examination again showed benign giant cell tumor without suspicion of malignancy.
  • CONCLUSION: In the literature the use of radiation therapy remains an appropriate therapy option in benign giant cell tumors with minimal adverse sequelae if primary surgical treatment is not feasible or fails.
  • [MeSH-major] Giant Cell Tumor of Bone / radiotherapy. Spinal Neoplasms / radiotherapy
  • [MeSH-minor] Female. Humans. Middle Aged. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / radiotherapy. Neoplasm Recurrence, Local / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16810546.001).
  • [ISSN] 0936-8051
  • [Journal-full-title] Archives of orthopaedic and trauma surgery
  • [ISO-abbreviation] Arch Orthop Trauma Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


8. Puri A, Agarwal M: Treatment of giant cell tumor of bone: Current concepts. Indian J Orthop; 2007 Apr;41(2):101-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of giant cell tumor of bone: Current concepts.
  • Giant cell tumor (GCT) of bone though one of the commonest bone tumors encountered by an orthopedic surgeon continues to intrigue treating surgeons.
  • Usually benign, they are locally aggressive and may occasionally undergo malignant transformation.
  • The surgeon needs to strike a balance during treatment between reducing the incidence of local recurrence while preserving maximal function.Differing opinions pertaining to the use of adjuvants for extension of curettage, the relative role of bone graft or cement to pack the defect and the management of recurrent lesions are some of the issues that offer topics for eternal debate.Current literature suggests that intralesional curettage strikes the best balance between controlling disease and preserving optimum function in the majority of the cases though there may be occasions where the extent of the disease mandates resection to ensure adequate disease clearance.An accompanying treatment algorithm helps outline the management strategy in GCT.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21139760.001).
  • [ISSN] 0019-5413
  • [Journal-full-title] Indian journal of orthopaedics
  • [ISO-abbreviation] Indian J Orthop
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2989131
  • [Keywords] NOTNLM ; Curettage / giant cell tumor / treatment
  •  go-up   go-down


9. Swanger R, Maldjian C, Murali R, Tenner M: Three cases of benign giant cell tumor with unusual imaging features. Clin Imaging; 2008 Sep-Oct;32(5):407-10
MedlinePlus Health Information. consumer health - Spine Injuries and Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Three cases of benign giant cell tumor with unusual imaging features.
  • OBJECTIVE: Imaging findings for giant cell tumors (GCT) of the spine displaying aggressive characteristics have not been widely reported.
  • CONCLUSION: Acute fracture, subluxation, and extension through the disc space have not been previously described and, while atypical for benign lesions, may in fact be typical for GCT of the spine.
  • [MeSH-major] Fractures, Spontaneous / diagnosis. Giant Cell Tumor of Bone / diagnosis. Spinal Cord Compression / diagnosis. Spinal Fractures / diagnosis. Spinal Neoplasms / diagnosis
  • [MeSH-minor] Adult. Biopsy, Needle. Female. Follow-Up Studies. Humans. Immunohistochemistry. Low Back Pain / diagnosis. Low Back Pain / etiology. Magnetic Resonance Imaging / methods. Retrospective Studies. Risk Assessment. Sampling Studies. Tomography, X-Ray Computed / methods. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18760733.001).
  • [ISSN] 1873-4499
  • [Journal-full-title] Clinical imaging
  • [ISO-abbreviation] Clin Imaging
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Pavlovic S, Valyi-Nagy T, Profirovic J, David O: Fine-needle aspiration of brown tumor of bone: cytologic features with radiologic and histologic correlation. Diagn Cytopathol; 2009 Feb;37(2):136-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fine-needle aspiration of brown tumor of bone: cytologic features with radiologic and histologic correlation.
  • We report the case of a 40-year-old man with tertiary hyperparathyroidism due to end stage renal disease who initially presented with acute-onset paraplegia, elevated serum parathyroid hormone, and multiple bone abnormalities, including a large extradural intraspinal mass seen by magnetic resonance imaging.
  • In contrast with imaging features, fine-needle aspiration cytology showed numerous benign-appearing multinucleated osteoclast-type giant cells that are the characteristics of either brown tumor or benign giant cell tumor of bone.
  • A core-needle biopsy confirmed the diagnostic features of brown tumor of hyperparathyroidism.
  • [MeSH-major] Bone Neoplasms / diagnosis. Giant Cell Tumor of Bone / diagnosis
  • [MeSH-minor] Adult. Biopsy, Fine-Needle. Diagnosis, Differential. Humans. Hyperparathyroidism / complications. Hyperparathyroidism / diagnosis. Hyperparathyroidism / pathology. Male. Osteoclasts / pathology

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19021196.001).
  • [ISSN] 1097-0339
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Ech-Charif S, Aubert S, Buob D, Verhulst P, Blomme V, Migaud H, Leroy X: [Giant cell tumor of soft tissues. Report of two cases]. Ann Pathol; 2006 Feb;26(1):26-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Giant cell tumor of soft tissues. Report of two cases].
  • [Transliterated title] Tumeur à cellules géantes des tissus mous.
  • We report two cases of giant-cell tumour of soft tissue (TCG-TM).
  • The first case occurred in a 26-year-old woman presenting with a subcutaneous tumour of the left leg.
  • Pathological study revealed a tumour comparable to benign giant cell tumour of bone.
  • The patient is well without recurrence 10 months after the diagnosis.
  • Microscopically, the tumour was composed of sheets of mononuclear and multinucleated cells.
  • TCG-TMs are uncommon and represent a distinct entity whose clinical behaviour and histological features are similar to giant-cell tumour of bone.
  • The differential diagnosis includes other tumours rich in osteoclast-like cells.
  • [MeSH-major] Giant Cell Tumors / pathology. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Adult. Bone Neoplasms / pathology. Female. Giant Cells / pathology. Humans. Leukocytes, Mononuclear / pathology. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16841007.001).
  • [ISSN] 0242-6498
  • [Journal-full-title] Annales de pathologie
  • [ISO-abbreviation] Ann Pathol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


12. Kapoor SK, Jain V, Agrawal M, Singh S, Mandal AK: Primary malignant giant cell tumor of bone: a series of three rare cases. J Surg Orthop Adv; 2007;16(2):89-92
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary malignant giant cell tumor of bone: a series of three rare cases.
  • The purpose of this research was to study incidence; clinical, histological, and radiological features; and outcome of primary malignant giant cell tumor (PMGCT).
  • The authors retrospectively reviewed all cases of giant cell tumor (GCT) in which a diagnosis of GCT was related to sarcoma treated in their department between 1997 and 2004.
  • In these three cases of PMGCT, the initial clinical and radiological findings were the same as those for benign giant cell tumor.
  • Wide excision of the tumor was performed in all three cases.
  • Awareness about this entity, adequate biopsy, and sampling of specimen can aid in early diagnosis, which may improve the overall prognosis.
  • [MeSH-major] Bone Neoplasms / diagnosis. Giant Cell Tumor of Bone / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17592717.001).
  • [ISSN] 1548-825X
  • [Journal-full-title] Journal of surgical orthopaedic advances
  • [ISO-abbreviation] J Surg Orthop Adv
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


13. Gruenwald N, Demos TC, Lomasney LM, Rapp T: The case. Giant-cell tumor. Orthopedics; 2006 Feb;29(2):94, 167-71
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The case. Giant-cell tumor.
  • Giant-cell tumor is a benign but locally aggressive primary bone tumor that requires surgical management.
  • Most giant-cell tumors initially are demonstrated on radiographs as distal, subarticular, geographic osteolytic lesions.
  • Abundant giant cells on histology are reactive secondary to a neoplastic fibroblast-like stromal cell.
  • Giant cells are present in many neoplastic and non-neoplastic bone lesions; therefore the diagnosis of giant-cell tumors requires correlation of clinical, imaging, and pathologic data to exclude other lesions that demonstrate a similar histologic pattern.
  • A small number of giant-cell tumors result in lung lesions, many of which have benign histology, can be treated by wedge resection, and do not affect long-term outcome.
  • [MeSH-major] Bone Neoplasms / radiography. Giant Cell Tumor of Bone / radiography. Knee

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16485448.001).
  • [ISSN] 0147-7447
  • [Journal-full-title] Orthopedics
  • [ISO-abbreviation] Orthopedics
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


1
Advertisement
4. Harrop JS, Schmidt MH, Boriani S, Shaffrey CI: Aggressive "benign" primary spine neoplasms: osteoblastoma, aneurysmal bone cyst, and giant cell tumor. Spine (Phila Pa 1976); 2009 Oct 15;34(22 Suppl):S39-47
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aggressive "benign" primary spine neoplasms: osteoblastoma, aneurysmal bone cyst, and giant cell tumor.
  • OBJECTIVE: To define optimal clinical care for primary spinal aggressive "benign" osseous neoplasms using a systematic review with expert opinion.
  • METHODS: Predefined focused questions on treatment of osteoblastomas, aneurysmal bone cysts and giant cell tumors were refined by a panel of spine oncology surgeons, medical and radiation oncologist.
  • The aneurysmal bone cysts initial search revealed 482 articles initially of which 6 were pertinent; and the search on giant cell tumors identified 178 articles of which only 8 were focused on the predefined treatment questions.
  • CONCLUSION: Spinal aggressive benign osseous neoplasms have varying histology.
  • Despite these differences surgical treatment should be directed at gross resection of the tumor, understanding that this may be limited by anatomic confines and the potential for morbidity.
  • [MeSH-major] Bone Cysts, Aneurysmal / therapy. Giant Cell Tumor of Bone / therapy. Osteoblastoma / therapy. Spinal Diseases / therapy. Spinal Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Spine Injuries and Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19829276.001).
  • [ISSN] 1528-1159
  • [Journal-full-title] Spine
  • [ISO-abbreviation] Spine
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 82
  •  go-up   go-down


15. Shigematsu K, Kobata Y, Yajima H, Kawamura K, Maegawa N, Takakura Y: Giant-cell tumors of the carpus. J Hand Surg Am; 2006 Sep;31(7):1214-9
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant-cell tumors of the carpus.
  • Giant cell tumor (GCT) of bone is a rare, benign tumor with some aggressive characteristics such as a high recurrence rate.
  • The tumor usually occurs in the distal radius although it has been reported in the carpus.
  • We reviewed 63 manuscripts published from 1935 to 2005 and report on the treatment of GCT of carpal bone in 29 cases.
  • [MeSH-major] Bone Neoplasms / surgery. Carpal Bones / surgery. Giant Cell Tumor of Bone / surgery
  • [MeSH-minor] Amputation. Bone Transplantation. Cryosurgery. Curettage. Humans. Neoplasm Recurrence, Local

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16945730.001).
  • [ISSN] 0363-5023
  • [Journal-full-title] The Journal of hand surgery
  • [ISO-abbreviation] J Hand Surg Am
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 38
  •  go-up   go-down


16. Turcotte RE: Giant cell tumor of bone. Orthop Clin North Am; 2006 Jan;37(1):35-51
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant cell tumor of bone.
  • Giant cell tumor is a common benign bone tumor that possesses specific features including location at the end of long bone, a strong tendency toward local recurrence, and the rare capacity to metastasize to the lungs.
  • Preferred treatment usually consists of extensive curettage and filling of the cavity with bone graft or cement.
  • [MeSH-major] Bone Neoplasms / pathology. Bone Neoplasms / surgery. Fractures, Spontaneous / pathology. Giant Cell Tumor of Bone / pathology. Giant Cell Tumor of Bone / surgery. Neoplasm Recurrence, Local / pathology
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Bone Transplantation / methods. Combined Modality Therapy. Curettage / methods. Female. Humans. Incidence. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Staging. Prognosis. Risk Assessment. Sex Distribution. Tomography, X-Ray Computed. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16311110.001).
  • [ISSN] 0030-5898
  • [Journal-full-title] The Orthopedic clinics of North America
  • [ISO-abbreviation] Orthop. Clin. North Am.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 123
  •  go-up   go-down


17. Mendenhall WM, Zlotecki RA, Scarborough MT, Gibbs CP, Mendenhall NP: Giant cell tumor of bone. Am J Clin Oncol; 2006 Feb;29(1):96-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant cell tumor of bone.
  • OBJECTIVE: To discuss the treatment and outcomes for giant cell tumor (GCT) of bone.
  • RESULTS: GCT is a rare benign bone lesion most often found in the extremities of women in the third and fourth decades of life.
  • [MeSH-major] Bone Neoplasms / pathology. Bone Neoplasms / surgery. Giant Cell Tumor of Bone / pathology. Giant Cell Tumor of Bone / surgery
  • [MeSH-minor] Curettage. Diagnosis, Differential. Humans. Neoplasm Staging. Prognosis. Radiotherapy, Adjuvant

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16462511.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 25
  •  go-up   go-down


18. Lazaretti NS, Dallagasperina VW, Villaroel RU, Schlittler LA: [Giant cell tumour of distal femur with pulmonary metastases]. Rev Port Pneumol; 2010 Mar-Apr;16(2):331-7
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Giant cell tumour of distal femur with pulmonary metastases].
  • [Transliterated title] Tumor de células gigantes de fémur distal com metástases pulmonares.
  • Gian cell is normally a benign primary skeletal lesion located in the epiphysis of the long bones.
  • It is more frequente in the third and fourth decades of life but can exhibit the behaviour of a malignant tumour with distal metatasis.
  • The treatment of primary tumour is extensive surgical resection.
  • We report a case of a 35-year-old patient with lung metatases 21 months after curettage of giant cell tumour in distal femur.
  • [MeSH-major] Femoral Neoplasms / pathology. Giant Cell Tumor of Bone / secondary. Lung Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20437009.001).
  • [ISSN] 2172-6825
  • [Journal-full-title] Revista portuguesa de pneumologia
  • [ISO-abbreviation] Rev Port Pneumol
  • [Language] por
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Portugal
  •  go-up   go-down


19. Arroud M, Afifi MA, Chbani L, Riffi AA, Bouabdallah Y: Giant-cell tumor of the fourth metacarpal bone in children: case report. J Pediatr Orthop B; 2010 Jan;19(1):86-9
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant-cell tumor of the fourth metacarpal bone in children: case report.
  • Giant-cell tumor is a rare benign tumor that generally arises in long bones of the lower extremity in adults.
  • The involvement of the metacarpal bone in children is extremely rare.
  • The authors report the case of an 8-year-old boy admitted for a painless swelling of the posterior surface of the fourth right metacarpal bone.
  • Total resection of the metacarpal bone and reconstruction with free fibular graft was performed.
  • [MeSH-major] Bone Neoplasms / pathology. Giant Cell Tumor of Bone / pathology. Metacarpal Bones / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Pediatr Orthop B. 2010 May;19(3):285-6 [20375665.001]
  • (PMID = 19898253.001).
  • [ISSN] 1473-5865
  • [Journal-full-title] Journal of pediatric orthopedics. Part B
  • [ISO-abbreviation] J Pediatr Orthop B
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Liang X, Jiang D, Ni W: [Clinical observation on nano-hydroxyapatite and polyamide 66 composite in repairing bone defect due to benign bone tumor]. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2007 Aug;21(8):785-8
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical observation on nano-hydroxyapatite and polyamide 66 composite in repairing bone defect due to benign bone tumor].
  • OBJECTIVE: To observe the clinical effect and safety of the nano-hydroxyapatite/polyamide 66 (n-HA/PA66) composite in repairing the bone defects due to benign bone tumors.
  • METHODS: From January 2003 to May 2005, 38 patients (21 males, 16 females; age, 19-58 years, averaged 38.5 years) with the bone defects due to benign bone tumors were treated with the n-HA/PA66 grains.
  • Among the 37 patients, 11 had fibrous dysplasia, 14 had bone cyst, 10 had giant cell tumor of the bone (Grade I ), and 2 had enchondroma.
  • The tumors ranged in size from 1.0 cm x 0.7 cm x 0.4 cm to 10.0 cm x 4.0 cm x 3.0 cm, with the location of the proximal femur in 12 patients, the distal femur in 7, the proximal tibia in 9, the proximal humerus in 5, the phalanges of the finger in 2, the metacarpal bone in 1, and the calcaneus in 1.
  • All the benign bone tumors underwent the curettage treatment, and then the tumor cavities were filled up with the n-HA/PA66 grains.
  • The incision healing, local inflammatory reaction, rejection, toxic reaction, tumor cavity healing, and function recovery of the limbs were all observed after operation.
  • At 3 to 5.5 months(mean 4 months) after operation, osteogenesis was found in the space filled with the n-HA/PA66 grains.
  • CONCLUSION: The n-HA/PA66 grains have great biological safety, good biocompatibility, and good bone conduction, which are good materials for the bone repair and reconstruction, and can be safely, and effectively used for repairing the bone defects due to benign bone tumors.
  • [MeSH-major] Bone Neoplasms / surgery. Bone Substitutes. Hydroxyapatites. Nylons
  • [MeSH-minor] Adult. Biocompatible Materials. Bone Cysts / surgery. Female. Follow-Up Studies. Giant Cell Tumor of Bone / surgery. Humans. Male. Middle Aged. Nanostructures. Reconstructive Surgical Procedures / methods. Treatment Outcome. Wound Healing. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17882867.001).
  • [ISSN] 1002-1892
  • [Journal-full-title] Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery
  • [ISO-abbreviation] Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biocompatible Materials; 0 / Bone Substitutes; 0 / Hydroxyapatites; 0 / Nylons
  •  go-up   go-down


21. Li Y, Liang Q, Wen YQ, Chen LL, Wang LT, Liu YL, Luo CQ, Liang HZ, Li MT, Li Z: Comparative proteomics analysis of human osteosarcomas and benign tumor of bone. Cancer Genet Cytogenet; 2010 Apr 15;198(2):97-106
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative proteomics analysis of human osteosarcomas and benign tumor of bone.
  • Proteins extracted from osteosarcoma tissue and benign bone tumors, including osteoblastoma, chondroblastoma, and giant cell tumor of bone, were examined using two-dimensional gel electrophoresis followed by mass spectrometry analysis and database searches.
  • Aberrant expression of cytoskeletal- and microtubule-associated proteins in osteosarcoma may provide an advantage for tumor invasion and metastasis by affecting the stability of microtubule, which consequently influences the prognosis of patients.
  • [MeSH-major] Bone Neoplasms / metabolism. Neoplasm Proteins / analysis. Osteoblastoma / metabolism. Osteosarcoma / metabolism. Proteomics / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Biomarkers, Tumor / analysis. Biomarkers, Tumor / metabolism. Bone and Bones / metabolism. Bone and Bones / pathology. Child. Chondroblastoma / metabolism. Chondroblastoma / pathology. Female. Giant Cell Tumor of Bone / metabolism. Giant Cell Tumor of Bone / pathology. Humans. Male. Middle Aged. Proteome / analysis. Proteome / metabolism. Young Adult


22. McGough RL, Rutledge J, Lewis VO, Lin PP, Yasko AW: Impact severity of local recurrence in giant cell tumor of bone. Clin Orthop Relat Res; 2005 Sep;438:116-22
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact severity of local recurrence in giant cell tumor of bone.
  • We retrospectively reviewed 183 consecutive patients diagnosed with giant cell tumor at the three most common sites (distal femur, proximal tibia, and distal radius) to determine the pattern of local tumor recurrence and the impact severity of the recurrence on adjacent joint function.
  • The primary tumor was treated in all patients with intralesional excision of tumor by curettage.
  • The intrainstitutional recurrences were salvaged by a repeat curettage (n = 12) or en bloc osteoarticular resection (n = 10) for bone recurrences and wide local excision for soft tissue recurrence (n = 1).
  • The prereferral recurrences were salvaged by a repeat curettage (n = 7) and en bloc osteoarticular resection (n = 15) for bone recurrences.
  • Incomplete initial surgery, a delay in diagnosis of the recurrence of greater than 6 months, and subchondral recurrence of tumor were contributing factors in the failure to salvage the joint.
  • Despite its benign histology, giant cell tumor of bone is an aggressive tumor that demands meticulous attention to surgical detail and close postoperative surveillance for successful local tumor control and durable, joint-preserving function.
  • [MeSH-major] Bone Neoplasms / pathology. Giant Cell Tumor of Bone / pathology. Neoplasm Recurrence, Local

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16131879.001).
  • [ISSN] 0009-921X
  • [Journal-full-title] Clinical orthopaedics and related research
  • [ISO-abbreviation] Clin. Orthop. Relat. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Sah PL, Sharma R, Kandpal H, Seith A, Rastogi S, Bandhu S, Jagannathan NR: In vivo proton spectroscopy of giant cell tumor of the bone. AJR Am J Roentgenol; 2008 Feb;190(2):W133-9
Hazardous Substances Data Bank. CHOLINE CHLORIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vivo proton spectroscopy of giant cell tumor of the bone.
  • OBJECTIVE: The proton MR spectroscopic finding of elevated choline has been reported to be useful in the differentiation of malignant from benign musculoskeletal tumors.
  • This study was designed to evaluate the MR spectroscopy features of giant cell tumor (GCT) of the bone, primarily to determine whether the presence of choline is a frequent occurrence in these tumors and whether MR spectroscopy features can be correlated with clinical, radiologic, and histopathologic findings.
  • SUBJECTS AND METHODS: MRI, dynamic contrast-enhanced MRI, and proton MR spectroscopy were performed in 33 patients with bone tumors on a 1.5-T MR scanner.
  • Of these, 12 patients who had GCT of the bone form the subject material for this study.
  • RESULTS: Although all 12 tumors were benign on histopathology, four had elevated choline levels.
  • CONCLUSION: The results of this study indicate that GCT of bone may show raised choline levels on proton MR spectroscopy.
  • [MeSH-major] Biomarkers, Tumor / analysis. Bone Neoplasms / diagnosis. Bone Neoplasms / metabolism. Carcinoma, Giant Cell / diagnosis. Carcinoma, Giant Cell / metabolism. Choline / analysis. Magnetic Resonance Spectroscopy / methods

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18212197.001).
  • [ISSN] 1546-3141
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Protons; N91BDP6H0X / Choline
  •  go-up   go-down


24. Wong KC, Kumta SM, Tse LF, Ng EW, Lee KS: Navigation Endoscopic Assisted Tumor (NEAT) surgery for benign bone tumors of the extremities. Comput Aided Surg; 2010;15(1-3):32-9
MedlinePlus Health Information. consumer health - Endoscopy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Navigation Endoscopic Assisted Tumor (NEAT) surgery for benign bone tumors of the extremities.
  • A novel technique of using both a navigation system and an endoscope in intra-lesional curettage of benign bone tumors enables safe and adequate tumor removal via a minimal access approach.
  • We performed curettage of benign bone tumors in five consecutive patients (4 female, 1 male, mean age 31.4 years) using a commercial CT-based navigation system supplemented by visual guidance through a shoulder arthroscope.
  • The bone defect was filled with bone cement in four patients and with artificial bone substitute in one patient.
  • [MeSH-major] Bone Neoplasms / surgery. Chondroblastoma / surgery. Endoscopy / methods. Extremities / surgery. Giant Cell Tumor of Bone / surgery. Surgery, Computer-Assisted / methods

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20433316.001).
  • [ISSN] 1097-0150
  • [Journal-full-title] Computer aided surgery : official journal of the International Society for Computer Aided Surgery
  • [ISO-abbreviation] Comput. Aided Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  •  go-up   go-down


25. Cai G, Ramdall R, Garcia R, Levine P: Pulmonary metastasis of giant cell tumor of the bone diagnosed by fine-needle aspiration biopsy. Diagn Cytopathol; 2007 Jun;35(6):358-62
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulmonary metastasis of giant cell tumor of the bone diagnosed by fine-needle aspiration biopsy.
  • Giant cell tumor is a benign but locally aggressive tumor that primarily affects the epiphyses of long bones of young adults.
  • Pulmonary metastases in giant cell tumor are rare (about 1-9%).
  • Here, we report a case of metastatic pulmonary giant cell tumor in a patient who had a previous history of giant cell tumor of the distal femur with multiple recurrences.
  • The diagnosis of pulmonary metastasis was achieved by cytologic evaluation with concurrent immunohistochemical studies in material obtained by fine-needle aspiration biopsy.
  • The aspirate smears contained clustered and dispersed mononuclear and osteoclast-like giant cells that had bland nuclei with inconspicuous nucleoli.
  • The pulmonary metastasis was similar morphologically and immunophenotypically to the recurrent giant cell tumor of the bone.
  • [MeSH-major] Bone Neoplasms / pathology. Giant Cell Tumor of Bone / pathology. Lung Neoplasms / diagnosis. Lung Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17497658.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. Lee VN, Nithyananth M, Cherian VM, Amritanand R, Venkatesh K, Sundararaj GD, Raghuram LN: Preoperative embolisation in benign bone tumour excision. J Orthop Surg (Hong Kong); 2008 Apr;16(1):80-3
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative embolisation in benign bone tumour excision.
  • PURPOSE: To assess the role of preoperative embolisation in benign bone tumour excision.
  • METHODS: 3 men and 3 women aged 19 to 35 (mean 23) years with either a giant cell tumour or an aneurysmal bone cyst in limb girdle sites underwent preoperative embolisation a day prior to wide local excision by the same surgeon.
  • Tumour size, blood loss, wound healing, infection, and tumour recurrence were assessed.
  • No tumour recurred within a minimum 5-year follow-up.
  • CONCLUSION: Preoperative embolisation is useful in the management of vascular and aggressive bone tumours located at limb girdle sites where a tourniquet cannot be used.
  • [MeSH-major] Bone Cysts, Aneurysmal / surgery. Bone Neoplasms / surgery. Embolization, Therapeutic. Giant Cell Tumor of Bone / surgery. Preoperative Care

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18453665.001).
  • [ISSN] 1022-5536
  • [Journal-full-title] Journal of orthopaedic surgery (Hong Kong)
  • [ISO-abbreviation] J Orthop Surg (Hong Kong)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


32. Domovitov SV, Healey JH: Primary malignant giant-cell tumor of bone has high survival rate. Ann Surg Oncol; 2010 Mar;17(3):694-701
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary malignant giant-cell tumor of bone has high survival rate.
  • BACKGROUND: Malignant giant-cell tumors (MGCT) comprise 2-9% of all giant-cell tumors (GCTs).
  • This study compared malignant to benign GCTs and defined the clinical outcome of the patients in a large series of case-matched patients from a single institution.
  • METHODS: Clinical, radiological, and outcome features were compared between 26 malignant and 244 benign GCTs treated in our institution.
  • We also performed a 1:2 case-matched comparison of patients with malignant and benign disease.
  • MGCT were less likely to have aneurysmal bone cyst changes.
  • The 5-year recurrence-free status probability was 80% for malignant and 91% for benign cases in matched groups.
  • The difference in the recurrence rate between benign and malignant groups was not statistically significant (P = 0.24).
  • Functional impairment and limited activity were greater in MGCT patients than in benign GCT patients, whether treated by resection/amputation or curettage/cryosurgery.
  • CONCLUSIONS: We found that malignant and benign GCT have similar epidemiology and that recurrence was higher in MGCT (20 v 9%).
  • [MeSH-major] Bone Neoplasms / mortality. Giant Cell Tumor of Bone / mortality. Neoplasm Recurrence, Local / mortality

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19902306.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


33. Miller IJ, Blank A, Yin SM, McNickle A, Gray R, Gitelis S: A case of recurrent giant cell tumor of bone with malignant transformation and benign pulmonary metastases. Diagn Pathol; 2010;5:62
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of recurrent giant cell tumor of bone with malignant transformation and benign pulmonary metastases.
  • Giant cell tumor (GCT) of bone is a locally destructive tumor that occurs predominantly in long bones of post-pubertal adolescents and young adults, where it occurs in the epiphysis.
  • Vascular invasion outside the boundary of the tumor can be seen.
  • Metastasis, with identical morphology to the primary tumor, occurs in a few percent of cases, usually to the lung.
  • On occasion GCTs of bone undergo frank malignant transformation to undifferentiated sarcomas.
  • Here we report a case of GCT of bone that at the time of recurrence was found to have undergone malignant transformation.
  • [MeSH-major] Bone Neoplasms / pathology. Cell Transformation, Neoplastic / pathology. Giant Cell Tumor of Bone / secondary. Lung Neoplasms / secondary. Neoplasm Recurrence, Local. Tibia / pathology
  • [MeSH-minor] Adult. Arthroplasty, Replacement, Knee. Biopsy. Bone Cements / therapeutic use. Chemotherapy, Adjuvant. Curettage. Humans. Immunohistochemistry. Male. Neoadjuvant Therapy. Reoperation. Thoracoscopy. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Bone Miner Res. 2000 Apr;15(4):640-9 [10780856.001]
  • [Cites] Ann Surg Oncol. 2010 Mar;17(3):694-701 [19902306.001]
  • [Cites] Clin Orthop Relat Res. 2002 Apr;(397):248-58 [11953616.001]
  • [Cites] Cancer. 2003 May 15;97(10):2520-9 [12733152.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Sep 1;57(1):158-65 [12909228.001]
  • [Cites] J Bone Joint Surg Br. 2004 Mar;86(2):212-6 [15046435.001]
  • [Cites] Int Orthop. 2004 Aug;28(4):239-43 [15160253.001]
  • [Cites] Cancer. 1970 May;25(5):1061-70 [4910256.001]
  • [Cites] J Bone Joint Surg Am. 1986 Sep;68(7):1073-9 [3745247.001]
  • [Cites] Skeletal Radiol. 1997 Apr;26(4):246-55 [9151375.001]
  • [Cites] Int Orthop. 1998;22(1):19-26 [9549577.001]
  • [Cites] Am J Pathol. 2005 Jul;167(1):117-28 [15972958.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jan 17;103(3):690-5 [16407111.001]
  • [Cites] J Bone Joint Surg Br. 2006 Apr;88(4):531-5 [16567792.001]
  • [Cites] J Bone Joint Surg Am. 2006 Sep;88(9):1998-2008 [16951117.001]
  • [Cites] Int Orthop. 2006 Dec;30(6):499-504 [16909252.001]
  • [Cites] Int Orthop. 2006 Dec;30(6):484-9 [17013643.001]
  • [Cites] Am J Surg Pathol. 2007 Jun;31(6):970-6 [17527089.001]
  • [Cites] J Pathol. 2008 Apr;214(5):555-63 [18278785.001]
  • [Cites] Mod Pathol. 2008 Apr;21(4):369-75 [18311114.001]
  • [Cites] Clin Orthop Relat Res. 2008 Sep;466(9):2081-91 [18543051.001]
  • [Cites] J Cancer Res Clin Oncol. 2008 Sep;134(9):969-78 [18322700.001]
  • [Cites] Genes Chromosomes Cancer. 2009 Jun;48(6):468-79 [19242928.001]
  • [Cites] Curr Opin Oncol. 2009 Jul;21(4):338-44 [19444102.001]
  • [Cites] Genes Chromosomes Cancer. 2009 Jul;48(7):583-602 [19396867.001]
  • [Cites] Zhonghua Bing Li Xue Za Zhi. 2009 May;38(5):312-5 [19575873.001]
  • [Cites] Clin Orthop Relat Res. 2010 Mar;468(3):827-33 [19597900.001]
  • [Cites] Skeletal Radiol. 2001 Feb;30(2):104-8 [11310196.001]
  • (PMID = 20860830.001).
  • [ISSN] 1746-1596
  • [Journal-full-title] Diagnostic pathology
  • [ISO-abbreviation] Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Bone Cements
  • [Other-IDs] NLM/ PMC2954972
  •  go-up   go-down


34. Singhal V, Sharma SC, Anil J, Sachan PK, Harsh M, Singhal S, Raghuvanshi S: Giant benign nodular hidradenoma of the shoulder: A rare tumor in orthopedic practice. Int J Shoulder Surg; 2010 Oct;4(4):93-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant benign nodular hidradenoma of the shoulder: A rare tumor in orthopedic practice.
  • A clear cell hidradenoma is a rare dermal tumor, which is believed to originate from the apical portion of the sweat glands.
  • We present a giant benign nodular hidradenoma presenting as painful restriction of the right shoulder joint in a 35-year-old male.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Korean J Radiol. 2010 Jul-Aug;11(4):490-2 [20592936.001]
  • [Cites] AJR Am J Roentgenol. 1990 Dec;155(6):1251-5 [2122675.001]
  • [Cites] J Bone Joint Surg Am. 1982 Jun;64(5):780-2 [6282887.001]
  • (PMID = 21655004.001).
  • [ISSN] 0973-6042
  • [Journal-full-title] International journal of shoulder surgery
  • [ISO-abbreviation] Int J Shoulder Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] South Africa
  • [Other-IDs] NLM/ PMC3100814
  • [Keywords] NOTNLM ; Axillary mass / nodular hidradenoma
  •  go-up   go-down


35. Horvai AE, Kramer MJ, Garcia JJ, O'Donnell RJ: Distribution and prognostic significance of human telomerase reverse transcriptase (hTERT) expression in giant-cell tumor of bone. Mod Pathol; 2008 Apr;21(4):423-30
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distribution and prognostic significance of human telomerase reverse transcriptase (hTERT) expression in giant-cell tumor of bone.
  • Giant-cell tumor of bone is considered a benign, locally aggressive and rarely metastasizing neoplasm of bone.
  • However, recent evidence suggests that activity of the telomerase enzyme complex correlates with recurrence in giant-cell tumor, although the subset of cells with telomerase activity in these heterogeneous tumors has not been defined.
  • In the present study, we investigated whether immunostaining for human telomerase reverse transcriptase, a component of the telomerase complex, correlates with outcome in giant-cell tumor and the distribution of telomerase reverse transcriptase staining in these tumors.
  • We analyzed 58 cases of giant-cell tumor for the presence and pattern of telomerase reverse transcriptase immunostaining, presence of soft tissue involvement and the type of initial surgery, and correlated these findings with recurrence-free survival and metastasis-free survival.
  • Specific staining with telomerase reverse transcriptase was present in 20 out of 58 tumors (35%) in the nuclei of mononuclear cells and, occasionally, osteoclast-like giant cells.
  • Therefore, telomerase reverse transcriptase expression may predict recurrence in giant-cell tumor insofar as positive immunostaining correlates with shorter recurrence-free survival and may be a useful prognostic marker to stratify patients to more aggressive treatment protocols.
  • [MeSH-major] Biomarkers, Tumor / analysis. Bone Neoplasms / enzymology. Giant Cell Tumor of Bone / enzymology. Telomerase / biosynthesis

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18204433.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.7.7.49 / TERT protein, human; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


36. Ozalp T, Yercan H, Okçu G, Ozdemir O, Coskunol E, Bégué T, Calli I: [Giant-cell tumor of the hand: midterm results in five patients]. Rev Chir Orthop Reparatrice Appar Mot; 2007 Dec;93(8):842-7
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Giant-cell tumor of the hand: midterm results in five patients].
  • [Transliterated title] Tumeur à cellules géantes de la main: résultats du traitement: 5 cas au recul moyen de 7, 8 ans.
  • PURPOSE OF THE STUDY: Giant-cell bone tumors are benign but have great potential for recurrence.
  • We examined the characteristic features of giant-cell tumors of the hand and analyzed the pertinence of surgical treatment.
  • We noted complications, consequences of recurrence and later operations on the same tumor site in five cases.
  • CASE REPORTS: Five patients treated between 1973 and 2000 for giant-cell tumors involving the hand bones were reviewed retrospectively.
  • The surgical procedure was curettage for two, curettage with bone graft for two and amputation for one.
  • In all six episodes of recurrent tumor were treated.
  • DISCUSSION: Treatment of giant-cell tumors involving the hand bones is designed to eradicate the tumor and also protect hand function while keeping in mind the aggressive nature of these benign tumors.
  • [MeSH-major] Bone Neoplasms / surgery. Giant Cell Tumors / surgery. Hand Bones / surgery
  • [MeSH-minor] Adult. Aged. Amputation. Bone Transplantation. Curettage. Female. Finger Phalanges / surgery. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / surgery. Retrospective Studies. Soft Tissue Neoplasms / surgery. Thumb / surgery. Time Factors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18166957.001).
  • [ISSN] 0035-1040
  • [Journal-full-title] Revue de chirurgie orthopédique et réparatrice de l'appareil moteur
  • [ISO-abbreviation] Rev Chir Orthop Reparatrice Appar Mot
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


37. Notarianni C, Abreo F, Nanda A: Cranial vault metastasis of giant cell tumor. Ann Diagn Pathol; 2008 Aug;12(4):286-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cranial vault metastasis of giant cell tumor.
  • Giant cell tumors are benign bony tumors involving the epiphysis of long bones.
  • Here, we present a case of giant cell tumor involving the parietal bone that had metastasized from the sacrum.
  • As we have presented here, cranial vault metastases can occur and should be considered in a differential diagnosis of bony lesions found in this location.
  • [MeSH-major] Giant Cell Tumor of Bone / pathology. Parietal Bone / pathology. Sacrum / pathology. Skull Neoplasms / secondary. Spinal Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18620997.001).
  • [ISSN] 1532-8198
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


38. Cordeiro SZ, Cordeiro Pde B, Sousa AM, Lannes DC, Pierro GS: Giant cell tumor of the rib occupying the entire hemithorax. J Bras Pneumol; 2008 Mar;34(3):185-8
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant cell tumor of the rib occupying the entire hemithorax.
  • The authors report the case of a 28-year-old female patient with a giant cell tumor originating from the rib.
  • The tumor, measuring 25 x 17 cm, occupied the entire hemithorax and caused atelectasis of the left lung.
  • This tumor was a benign mesenchymal neoplasm, which rarely affects the ribs.
  • A thoracotomy involving en bloc resection of the chest wall and tumor was performed.
  • Despite the large dimensions of the tumor, complete resection was possible, and lung function was restored.
  • [MeSH-major] Bone Neoplasms / diagnosis. Giant Cell Tumor of Bone / diagnosis. Ribs

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18392468.001).
  • [ISSN] 1806-3756
  • [Journal-full-title] Jornal brasileiro de pneumologia : publicaça̋o oficial da Sociedade Brasileira de Pneumologia e Tisilogia
  • [ISO-abbreviation] J Bras Pneumol
  • [Language] eng; por
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


39. Cosso R, Nuzzo V, Zuccoli A, Brandi ML, Falchetti A: Giant cell tumor in a case of Paget's disease of bone: an aggressive benign tumor exhibiting a quick response to an innovative therapeutic agent. Clin Cases Miner Bone Metab; 2010 May;7(2):145-52

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant cell tumor in a case of Paget's disease of bone: an aggressive benign tumor exhibiting a quick response to an innovative therapeutic agent.
  • Giant cell tumor of bone, also called osteoclastoma, is a rare skeletal complication of Paget's disease of bone.
  • We will focus on either a review on this rare bone tumor, including some genetic aspects, or the current established therapies.
  • Finally, we will describe the therapeutic outcomes of this unique complication of Paget's disease of bone as a rapid response to an innovative therapeutic agent.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22460021.001).
  • [ISSN] 1971-3266
  • [Journal-full-title] Clinical cases in mineral and bone metabolism : the official journal of the Italian Society of Osteoporosis, Mineral Metabolism, and Skeletal Diseases
  • [ISO-abbreviation] Clin Cases Miner Bone Metab
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Other-IDs] NLM/ PMC3004463
  •  go-up   go-down


40. Luther N, Bilsky MH, Härtl R: Giant cell tumor of the spine. Neurosurg Clin N Am; 2008 Jan;19(1):49-55
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant cell tumor of the spine.
  • Giant cell tumors are benign but locally aggressive neoplasms that typically affect the extremities.
  • Gross total resection of the tumor with wide margins yields good results in terms of survival.
  • Endovascular tumor embolizations have also been attempted to control unresectable tumors, and have been performed with moderate degrees of success.
  • Outcomes are analyzed outcomes following surgery, radiation therapy, and tumor embolization.
  • [MeSH-major] Giant Cell Tumor of Bone / pathology. Giant Cell Tumor of Bone / therapy. Spinal Neoplasms / pathology. Spinal Neoplasms / therapy. Spine / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18156047.001).
  • [ISSN] 1558-1349
  • [Journal-full-title] Neurosurgery clinics of North America
  • [ISO-abbreviation] Neurosurg. Clin. N. Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 29
  •  go-up   go-down


41. Forsyth RG, De Boeck G, Baelde JJ, Taminiau AH, Uyttendaele D, Roels H, Praet MM, Hogendoorn PC: CD33+ CD14- phenotype is characteristic of multinuclear osteoclast-like cells in giant cell tumor of bone. J Bone Miner Res; 2009 Jan;24(1):70-7
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD33+ CD14- phenotype is characteristic of multinuclear osteoclast-like cells in giant cell tumor of bone.
  • Giant cell tumor of bone (GCTB) is a benign bone tumor with a shown clinical behavior of local recurrences and rare distant metastases.
  • GCTB is composed of uniformly distributed osteoclastic giant cells, thought to originate from the fusion of monocyte-macrophage lineage cells, in a background consisting of mononuclear rounded cells and spindle-shaped cells.
  • Several reports showed the specific expression of markers, such as CD14 on the mononuclear rounded cell population, however, lacking osteoclastic giant cells.
  • Nineteen GCTB tumor samples of 19 patients were studied.
  • The mononuclear rounded cell population was positive for RANK, CD51, CD14, and CD33.
  • The osteoclastic giant cell population expressed RANK and CD51, as well as CD33, but was consistently negative for CD14 expression.
  • [MeSH-major] Antigens, CD / biosynthesis. Antigens, CD14 / biosynthesis. Antigens, Differentiation, Myelomonocytic / biosynthesis. Bone Neoplasms / metabolism. Giant Cell Tumors / metabolism. Osteoclasts / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18767926.001).
  • [ISSN] 1523-4681
  • [Journal-full-title] Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
  • [ISO-abbreviation] J. Bone Miner. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD14; 0 / Antigens, Differentiation, Myelomonocytic; 0 / CD33 protein, human; 0 / Integrin alphaV; 0 / Receptor Activator of Nuclear Factor-kappa B; 0 / Sialic Acid Binding Ig-like Lectin 3
  •  go-up   go-down


42. Prasad K, Rao SG, Harish K: Giant cell tumor of the temporal bone--a case report. BMC Ear Nose Throat Disord; 2005 Sep 15;5:8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant cell tumor of the temporal bone--a case report.
  • BACKGROUND: Giant cell tumor is a benign but locally aggressive bone neoplasm which uncommonly involves the skull.
  • The petrous portion of the temporal bone forms a rare location for this tumor.
  • CASE PRESENTATION: The authors report a case of a large giant cell tumor involving the petrous and squamous portions of the temporal bone in a 26 year old male patient.
  • Radical excision of the tumor was achieved but facial palsy could not be avoided.
  • CONCLUSION: Radical excision of skull base giant cell tumor may be hazardous but if achieved is the optimal treatment and may be curative.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Oral Maxillofac Surg. 2004 Jan;62(1):116-8 [14733232.001]
  • [Cites] Skeletal Radiol. 2005 Apr;34(4):225-8 [15365782.001]
  • [Cites] J Lab Clin Med. 2004 Oct;144(4):193-200 [15514587.001]
  • [Cites] J Orthop Res. 2005 Jan;23(1):203-9 [15607894.001]
  • [Cites] J Neurosurg. 1983 Aug;59(2):322-7 [6864300.001]
  • [Cites] J Orthop Res. 2000 Jul;18(4):647-54 [11052502.001]
  • [Cites] Neuroradiology. 1999 Apr;41(4):305-7 [10344520.001]
  • [Cites] Int J Oncol. 1999 Feb;14(2):291-300 [9917505.001]
  • [Cites] Histopathology. 1979 Nov;3(6):511-22 [511122.001]
  • [Cites] Surg Neurol. 1985 Jan;23(1):25-30 [3964973.001]
  • [Cites] J Oral Pathol Med. 1999 Feb;28(2):54-8 [9950250.001]
  • [Cites] J Neurosurg. 1994 Jan;80(1):148-51 [8271002.001]
  • [Cites] J Neurosurg. 1987 Jun;66(6):924-8 [3572521.001]
  • [Cites] Cancer. 1992 Sep 1;70(5):1124-32 [1515987.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1988 Aug;66(2):197-208 [3174054.001]
  • [Cites] Surg Neurol. 1978 Mar;9(3):185-8 [635765.001]
  • [Cites] Am J Pathol. 2005 Jul;167(1):117-28 [15972958.001]
  • [Cites] Indian J Cancer. 1991 Dec;28(4):177-80 [1818017.001]
  • [Cites] Surg Neurol. 1986 Jul;26(1):59-62 [3715701.001]
  • [Cites] Clin Orthop Relat Res. 2005 Jun;(435):211-8 [15930941.001]
  • [Cites] Neurosurgery. 1988 Jul;23 (1):120-2 [3173651.001]
  • [Cites] Am J Clin Pathol. 2002 Feb;117(2):210-6 [11863217.001]
  • (PMID = 16162299.001).
  • [ISSN] 1472-6815
  • [Journal-full-title] BMC ear, nose, and throat disorders
  • [ISO-abbreviation] BMC Ear Nose Throat Disord
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1253509
  •  go-up   go-down


43. Thomas DM, Skubitz KM: Giant cell tumour of bone. Curr Opin Oncol; 2009 Jul;21(4):338-44
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant cell tumour of bone.
  • PURPOSE OF REVIEW: Giant cell tumour of bone (GCT) is the most common benign bone tumour and afflicts a young population.
  • [MeSH-major] Bone Neoplasms / pathology. Bone Neoplasms / therapy. Giant Cell Tumor of Bone / pathology. Giant Cell Tumor of Bone / therapy

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19444102.001).
  • [ISSN] 1531-703X
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / RANK Ligand; 0 / TNFSF11 protein, human; 4EQZ6YO2HI / Denosumab
  • [Number-of-references] 60
  •  go-up   go-down


44. Marioni G, Marchese-Ragona R, Guarda-Nardini L, Stramare R, Tognazza E, Marino F, Staffieri A: Giant cell tumour (central giant cell lesion) of the maxilla. Acta Otolaryngol; 2006 Jul;126(7):779-81

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant cell tumour (central giant cell lesion) of the maxilla.
  • The giant cell tumour (GCT) is a benign, locally invasive lesion that accounts for about 20% of benign bone tumours.
  • Giant cell lesions in the craniofacial skeleton other than the jaws are uncommon; the majority of them occur in the sphenoid, ethmoid and temporal bones.
  • Our successful maxillary reconstruction based on the association between autologous calvarial bone sticks bent with titanium miniplates and a temporalis muscle pedicled flap allowed the involvement of only one donor area for both hard and soft tissues.
  • [MeSH-major] Giant Cell Tumor of Bone / diagnosis. Giant Cell Tumor of Bone / surgery. Maxillary Neoplasms / diagnosis. Maxillary Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16803721.001).
  • [ISSN] 0001-6489
  • [Journal-full-title] Acta oto-laryngologica
  • [ISO-abbreviation] Acta Otolaryngol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Norway
  •  go-up   go-down


45. Forsyth RG, De Boeck G, Bekaert S, De Meyer T, Taminiau AH, Uyttendaele D, Roels H, Praet MM, Hogendoorn PC: Telomere biology in giant cell tumour of bone. J Pathol; 2008 Apr;214(5):555-63
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Telomere biology in giant cell tumour of bone.
  • Giant cell tumour of bone (GCTB) is a benign bone tumour known for the unpredictable clinical behaviour of recurrences and, in rare instances, distant metastases.
  • It consists of uniformly distributed osteoclastic giant cells in a background of mononuclear rounded and spindle-shaped cells.
  • GCTB has often been regarded as a polyclonal tumour, but more recently a recurrent specific aberration was reported, which suggests a possible role for disturbed telomere maintenance.
  • Both osteoclastic giant cells and mononuclear cells showed positivity for hTERT and promyelocytic leukaemia body-related antigen.
  • These findings strongly suggest that these aggregates, while activating telomerase, are part of a structural telomere protective-capping mechanism rather than of a telomere-lengthening mechanism.
  • [MeSH-major] Bone Neoplasms / genetics. Giant Cell Tumors / genetics. Telomere / genetics
  • [MeSH-minor] Adolescent. Adult. Female. Humans. In Situ Hybridization, Fluorescence. Male. Microscopy, Confocal. Middle Aged. Neoplasm Proteins / metabolism. Nuclear Proteins / metabolism. Osteoclasts / metabolism. Osteoclasts / pathology. Phosphoproteins / metabolism. RNA-Binding Proteins / metabolism. Telomerase / metabolism. Transcription Factors / metabolism. Tumor Suppressor Proteins / metabolism

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2008 Pathological Society of Great Britain and Ireland
  • (PMID = 18278785.001).
  • [ISSN] 0022-3417
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / Nuclear Proteins; 0 / Phosphoproteins; 0 / RNA-Binding Proteins; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins; 0 / nucleolin; 143220-95-5 / PML protein, human; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


46. Jones KB, DeYoung BR, Morcuende JA, Buckwalter JA: Ethanol as a local adjuvant for giant cell tumor of bone. Iowa Orthop J; 2006;26:69-76
Hazardous Substances Data Bank. ETHANOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ethanol as a local adjuvant for giant cell tumor of bone.
  • Giant cell tumor is an aggressive benign neoplasm of bone.
  • No report on its use in a group of patients with giant cell tumor is available.
  • Records were retrospectively reviewed for all giant cell tumors treated by intralesional curettage and high concentration ethanol irrigation as the only chemical adjuvant.
  • Twenty-five primary excisional curettages and 12 repeat curettages for giant cell tumors of bone were performed in 31 patients.
  • Only use of a high-speed burr and lower Campanacci staging correlated with reduced recurrence rate, and these were not statistically significant.
  • In the 11 patients treated primarily with curettage using a high-speed burr and adjuvant ethanol with minimum two-year follow-up, only one stage 3 lesion in a distal radius recurred.
  • [MeSH-major] Bone Neoplasms / therapy. Ethanol / therapeutic use. Giant Cell Tumor of Bone / therapy

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Bone Joint Surg Br. 1996 Nov;78(6):984-5 [8951020.001]
  • [Cites] Clin Orthop Relat Res. 1996 Jul;(328):294-303 [8653971.001]
  • [Cites] Bull Hosp Jt Dis. 1998;57(1):6-10 [9553696.001]
  • [Cites] World J Surg. 1998 May;22(5):432-7 [9564283.001]
  • [Cites] Changgeng Yi Xue Za Zhi. 1998 Mar;21(1):37-43 [9607262.001]
  • [Cites] Jpn J Clin Oncol. 1998 May;28(5):323-8 [9703860.001]
  • [Cites] Clin Orthop Relat Res. 1999 Feb;(359):176-88 [10078141.001]
  • [Cites] J Bone Joint Surg Am. 1999 Jun;81(6):811-20 [10391546.001]
  • [Cites] Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi. 1998 Sep;12(5):280-2 [10437104.001]
  • [Cites] Bull Hosp Jt Dis. 1999;58(2):98-104 [10509202.001]
  • [Cites] Clin Orthop Relat Res. 2005 Jun;(435):211-8 [15930941.001]
  • [Cites] Clin Orthop Relat Res. 2005 Sep;438:123-7 [16131880.001]
  • [Cites] Eur J Surg Oncol. 1999 Dec;25(6):610-8 [10556009.001]
  • [Cites] Clin Orthop Relat Res. 2001 Feb;(383):221-8 [11210959.001]
  • [Cites] Eur J Surg Oncol. 2001 Mar;27(2):200-2 [11289759.001]
  • [Cites] Clin Orthop Relat Res. 2002 Apr;(397):248-58 [11953616.001]
  • [Cites] Clin Orthop Relat Res. 2002 Apr;(397):259-70 [11953617.001]
  • [Cites] J Orthop Sci. 2002;7(2):194-8 [11956979.001]
  • [Cites] Clin Orthop Relat Res. 2002 Jul;(400):201-10 [12072763.001]
  • [Cites] Iowa Orthop J. 2002;22:35-8 [12180608.001]
  • [Cites] Ann R Coll Surg Engl. 2004 Jan;86(1):18-24 [15005940.001]
  • [Cites] J Hand Surg Am. 2004 Mar;29(2):188-93 [15043887.001]
  • [Cites] J Bone Joint Surg Br. 2004 Mar;86(2):212-6 [15046435.001]
  • [Cites] Clin Orthop Relat Res. 2004 Jul;(424):221-6 [15241169.001]
  • [Cites] Int Orthop. 2004 Aug;28(4):239-43 [15160253.001]
  • [Cites] J Bone Joint Surg Am. 1970 Jun;52(4):619-64 [5479455.001]
  • [Cites] Cancer. 1978 Mar;41(3):957-69 [638982.001]
  • [Cites] Cancer. 1980 Oct 1;46(7):1641-9 [7417958.001]
  • [Cites] J Bone Joint Surg Am. 1982 Jun;64(5):755-61 [7045129.001]
  • [Cites] J Bone Joint Surg Am. 1983 Apr;65(4):486-90 [6833323.001]
  • [Cites] Acta Orthop Scand. 1984 Apr;55(2):209-14 [6369866.001]
  • [Cites] AJR Am J Roentgenol. 1985 May;144(5):955-60 [3872579.001]
  • [Cites] J Bone Joint Surg Am. 1986 Feb;68(2):235-42 [3511063.001]
  • [Cites] Bull Hosp Jt Dis Orthop Inst. 1988 Spring;48(1):93-101 [2840155.001]
  • [Cites] Chir Organi Mov. 1990;75(1 Suppl):204-5 [2249533.001]
  • [Cites] Chir Organi Mov. 1990;75(1 Suppl):206 [2249534.001]
  • [Cites] Chir Organi Mov. 1990;75(1 Suppl):212-3 [2249537.001]
  • [Cites] J Bone Joint Surg Am. 1994 Dec;76(12):1827-33 [7989388.001]
  • [Cites] J Bone Joint Surg Br. 1995 Mar;77(2):189-93 [7706330.001]
  • [Cites] J Hand Surg Am. 1995 May;20(3):432-40 [7642922.001]
  • [Cites] Clin Orthop Relat Res. 1995 Dec;(321):245-50 [7497676.001]
  • [Cites] Arch Orthop Trauma Surg. 1998;117(1-2):43-6 [9457335.001]
  • (PMID = 16789453.001).
  • [ISSN] 1541-5457
  • [Journal-full-title] The Iowa orthopaedic journal
  • [ISO-abbreviation] Iowa Orthop J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 3K9958V90M / Ethanol
  • [Other-IDs] NLM/ PMC1888590
  •  go-up   go-down


47. Albores-Saavedra J, Grider DJ, Wu J, Henson DE, Goodman ZD: Giant cell tumor of the extrahepatic biliary tree: a clinicopathologic study of 4 cases and comparison with anaplastic spindle and giant cell carcinoma with osteoclast-like giant cells. Am J Surg Pathol; 2006 Apr;30(4):495-500
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant cell tumor of the extrahepatic biliary tree: a clinicopathologic study of 4 cases and comparison with anaplastic spindle and giant cell carcinoma with osteoclast-like giant cells.
  • We report four previously undescribed primary giant cell tumors of the extrahepatic biliary tree and morphologically compare them with 10 anaplastic spindle and giant cell carcinomas with osteoclast-like giant cells of the gallbladder.
  • Two giant cell tumors were located in the distal common bile duct; one in the cystic duct and one in the gallbladder.
  • The 3 patients with bile duct tumors were male, and the only patient with a gallbladder tumor was a female.
  • The patients with bile duct tumors presented with biliary obstruction, and the patient with a gallbladder tumor presented with symptoms of cholelithiasis and a gallbladder mass.
  • Histologically, the tumors were similar to giant cell tumors of bone.
  • They consisted of a mixture of mononuclear and multinucleated osteoclast-like giant cells.
  • The mononuclear cells showed no atypical features, and their nuclei were similar to those of the multinucleated giant cells.
  • CD163 immunoreactivity was restricted to the mononuclear cells, whereas CD68 and HAM 56 labeled only the multinucleated osteoclast-like giant cells.
  • The anaplastic spindle and giant cell carcinomas contained a fewer number of osteoclast-like giant cells, and their mononuclear cells showed considerable variation in size and shape, marked cytologic atypia, and numerous mitotic figures.
  • The benign osteoclast-like giant cells showed immunoreactivity for CD68 and HAM 56 but were negative for CD163 and cytokeratins.
  • Giant cell tumors of the extrahepatic biliary tree are benign true histiocytic neoplasms that should be distinguished from the highly lethal anaplastic spindle and giant cell carcinomas with osteoclast-like giant cells by detailed cytologic analysis and immunohistochemical stains for CD163, CD68, HAM 56, and cytokeratins.
  • [MeSH-major] Bile Duct Neoplasms / pathology. Bile Ducts, Extrahepatic / pathology. Giant Cell Tumors / pathology
  • [MeSH-minor] Adenocarcinoma / diagnosis. Carcinoma / diagnosis. Cholestasis, Extrahepatic / etiology. Cholestasis, Extrahepatic / pathology. Cholestasis, Extrahepatic / surgery. Diagnosis, Differential. Disease-Free Survival. Female. Humans. Male. Middle Aged. Osteoclasts / pathology

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Am J Surg Pathol. 2008 Feb;32(2):335-7; author response 337 [18223338.001]
  • (PMID = 16625096.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


48. Yanagawa T, Watanabe H, Shinozaki T, Takagishi K: Curettage of benign bone tumors without grafts gives sufficient bone strength. Acta Orthop; 2009 Feb;80(1):9-13
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Curettage of benign bone tumors without grafts gives sufficient bone strength.
  • BACKGROUND AND PURPOSE: The defect that results after curettage of a bone tumor is usually filled in the same way.
  • We report the outcome in patients with benign bone tumors that were treated with curettage but no filling.
  • PATIENTS AND METHODS: We retrospectively studied 78 patients (mean age at the time of operation was 27 (6-73) years, 44 men) who had had a benign bone tumor curetted with no filling of the defect.
  • The commonest tumor types were giant cell tumor of bone (27), fibrous dysplasia (13), enchondroma (9), and simple bone cyst (7).
  • Local recurrence occurred in 9 patients; 7 of them had a giant cell tumor.
  • INTERPRETATION: Routine filling of curetted bone lesions does not appear to be necessary from a mechanical point of view.
  • [MeSH-major] Bone Neoplasms / surgery. Curettage / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Bone Cysts / surgery. Bone Remodeling / physiology. Follow-Up Studies. Giant Cell Tumor of Bone / surgery. Humans. Middle Aged. Neoplasm Recurrence, Local / surgery. Retrospective Studies. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Knee. 2002 Feb;9(1):73-5 [11830385.001]
  • [Cites] Acta Orthop. 2009 Feb;80(1):2-3 [19297784.001]
  • [Cites] Clin Orthop Relat Res. 2002 Apr;(397):248-58 [11953616.001]
  • [Cites] J Orthop Sci. 2002;7(2):194-8 [11956979.001]
  • [Cites] J Hand Surg Br. 2002 Oct;27(5):446-51 [12367544.001]
  • [Cites] Biomaterials. 2003 Jul;24(16):2739-47 [12711520.001]
  • [Cites] Arch Orthop Trauma Surg. 2004 Jun;124(5):301-5 [15014954.001]
  • [Cites] J Bone Joint Surg Br. 2004 Jul;86(5):719-25 [15274270.001]
  • [Cites] J Bone Joint Surg Am. 1981 Mar;63(3):367-75 [7204433.001]
  • [Cites] Clin Orthop Relat Res. 1985 Jan-Feb;(192):149-58 [3967417.001]
  • [Cites] Acta Orthop Scand. 1984 Dec;55(6):597-600 [6524324.001]
  • [Cites] Z Kinderchir. 1985 Aug;40(4):217-20 [3864319.001]
  • [Cites] J Bone Joint Surg Am. 1986 Feb;68(2):235-42 [3511063.001]
  • [Cites] Clin Orthop Relat Res. 1986 Mar;(204):45-58 [3514036.001]
  • [Cites] J Bone Joint Surg Am. 1987 Jan;69(1):106-14 [3805057.001]
  • [Cites] Clin Orthop Relat Res. 1988 Jan;(226):299-310 [3335103.001]
  • [Cites] Arch Orthop Trauma Surg. 1989;108(5):296-9 [2675797.001]
  • [Cites] Chir Organi Mov. 1990;75(1 Suppl):189-90 [2249528.001]
  • [Cites] Chir Organi Mov. 1990;75(1 Suppl):212-3 [2249537.001]
  • [Cites] J Hand Surg Am. 1991 Jan;16(1):139-42 [1995672.001]
  • [Cites] Arch Orthop Trauma Surg. 1992;111(2):61-5 [1562425.001]
  • [Cites] J Bone Joint Surg Am. 1994 Dec;76(12):1827-33 [7989388.001]
  • [Cites] Calcif Tissue Int. 1995 Jul;57(1):64-8 [7671168.001]
  • [Cites] Clin Orthop Relat Res. 1995 Dec;(321):245-50 [7497676.001]
  • [Cites] Arch Orthop Trauma Surg. 1996;115(1):45-8 [8775710.001]
  • [Cites] Clin Orthop Relat Res. 1999 Feb;(359):176-88 [10078141.001]
  • [Cites] J Bone Joint Surg Am. 1999 Jun;81(6):811-20 [10391546.001]
  • [Cites] Acta Orthop Scand. 1999 Jun;70(3):308-15 [10429612.001]
  • [Cites] Biomaterials. 2007 Jan;28(3):400-4 [17010424.001]
  • [Cites] Int Orthop. 2006 Dec;30(6):510-3 [16736145.001]
  • [Cites] Acta Orthop. 2008 Feb;79(1):86-93 [18283578.001]
  • [Cites] Acta Orthop. 2009 Feb;80(1):4-8 [19234881.001]
  • [CommentIn] Acta Orthop. 2009 Feb;80(1):2-3 [19297784.001]
  • (PMID = 19234882.001).
  • [ISSN] 1745-3682
  • [Journal-full-title] Acta orthopaedica
  • [ISO-abbreviation] Acta Orthop
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Sweden
  • [Other-IDs] NLM/ PMC2823236
  •  go-up   go-down


49. Saikia KC, Borgohain M, Bhuyan SK, Goswami S, Bora A, Ahmed F: Resection-reconstruction arthroplasty for giant cell tumor of distal radius. Indian J Orthop; 2010 Jul;44(3):327-32

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Resection-reconstruction arthroplasty for giant cell tumor of distal radius.
  • BACKGROUND: Giant cell tumor (GCT) of the distal radius poses problems for reconstruction after resection.
  • Here we have analyzed the results of aggressive benign GCTs of the distal radius treated by resection and reconstruction arthroplasty using autogenous non-vascularized fibular graft.
  • MATERIALS AND METHODS: Twenty-four cases of giant cell tumor of the distal radius (mean age 32 years, mean follow-up 6.6 years) treated by en-bloc resection and reconstruction arthroplasty using autogenous non-vascularized ipsilateral fibular graft with a minimum followup of two years have been included in this retrospective study.
  • Routine radiographs and clinical assessments regarding pain, instability, recurrence, hand grip strength and functional status were done at regular intervals and functional results were assessed using (musculoskeletal tumor society) MSTS-87 scoring.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int Orthop. 2009 Aug;33(4):1081-4 [19242692.001]
  • [Cites] Clin Orthop Relat Res. 2001 Feb;(383):221-8 [11210959.001]
  • [Cites] J Bone Joint Surg Br. 2006 Dec;88(12):1656-8 [17159183.001]
  • [Cites] J Hand Surg Br. 2005 Aug;30(4):369-73 [15951074.001]
  • [Cites] J Surg Oncol. 1998 Jun;68(2):100-3 [9624038.001]
  • [Cites] J Bone Joint Surg Am. 1994 Dec;76(12):1827-33 [7989388.001]
  • [Cites] J Bone Joint Surg Am. 1993 Nov;75(11):1648-55 [8245057.001]
  • [Cites] J Bone Joint Surg Am. 1993 Jun;75(6):899-908 [8314830.001]
  • [Cites] J Bone Joint Surg Am. 1986 Feb;68(2):235-42 [3511063.001]
  • [Cites] J Hand Surg Am. 1988 Sep;13(5):671-5 [3071544.001]
  • [Cites] Clin Orthop Relat Res. 1986 Mar;(204):45-58 [3514036.001]
  • [Cites] Clin Orthop Relat Res. 1987 May;(218):232-8 [3568485.001]
  • [Cites] J Bone Joint Surg Am. 1987 Jan;69(1):106-14 [3805057.001]
  • [Cites] J Bone Joint Surg Am. 1986 Jun;68(5):687-94 [3722225.001]
  • [Cites] J Bone Joint Surg Br. 1983 Nov;65(5):618-20 [6643568.001]
  • [Cites] J Bone Joint Surg Am. 1981 Jan;63(1):166-9 [7005238.001]
  • [Cites] J Bone Joint Surg Am. 1981 Jul;63(6):877-84 [7240328.001]
  • [Cites] J Hand Surg Am. 1977 Jul;2(4):299-308 [330615.001]
  • [Cites] Cancer. 1978 Mar;41(3):957-69 [638982.001]
  • [Cites] Cancer. 1970 May;25(5):1061-70 [4910256.001]
  • [Cites] J Bone Joint Surg Am. 1970 Jun;52(4):619-64 [5479455.001]
  • [Cites] J Hand Surg Am. 2004 Mar;29(2):188-93 [15043887.001]
  • [Cites] Int Orthop. 2003;27(2):110-3 [12700936.001]
  • [Cites] Plast Reconstr Surg. 2002 Jul;110(1):112-7 [12087240.001]
  • [Cites] Int Orthop. 2009 Feb;33(1):203-9 [17724593.001]
  • (PMID = 20697488.001).
  • [ISSN] 1998-3727
  • [Journal-full-title] Indian journal of orthopaedics
  • [ISO-abbreviation] Indian J Orthop
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2911935
  • [Keywords] NOTNLM ; Distal radius / giant cell tumor / resection reconstruction
  •  go-up   go-down


50. Haque AU, Moatasim A: Giant cell tumor of bone: a neoplasm or a reactive condition? Int J Clin Exp Pathol; 2008;1(6):489-501

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant cell tumor of bone: a neoplasm or a reactive condition?
  • Giant cell tumor of bone (GCTB) is a benign but locally aggressive bone tumor of young adults.
  • Microscopically areas of frank hemorrhage, numerous multinucleated giant cells and spindly stromal cells are present.
  • While giant cells and stromal cells have been extensively studied, little attention has been paid to the overwhelming hemorrhagic component.
  • If examined carefully intact and partially degenerated red blood cells are almost invariably seen in many giant cells as well as in the stroma.
  • While hemorrhage in many patients may be resolved without leaving any trace over time, in some it gives rise to giant cell formation, and in others it may lead to proliferation of fibroblasts and histiocytes.
  • Malignancy usually does not occur in GCTB and when discover, it usually represents primary bone sarcomas missed at original diagnosis.
  • Aneurysmal bone cyst (ABC) shares many features with GCTB.
  • There had been unique karyotypic changes in some aneurysmal bone cysts making it distinct from GCTB.
  • However these changes may be in the endothelial cells which are quite different from stromal or giant cells.
  • Enhanced telomerase activity and karyotypic aberrations may be necessary for rapid division of the nuclei of the giant cells in order to be able to deal with significant in situ intraosseous hemorrhage.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Diagn Cytopathol. 2002 Dec;27(6):375-8 [12451570.001]
  • [Cites] Mod Pathol. 2000 Nov;13(11):1206-10 [11106078.001]
  • [Cites] Histol Histopathol. 2001 Jan;16(1):297-307 [11193206.001]
  • [Cites] J Bone Miner Res. 2000 Apr;15(4):640-9 [10780856.001]
  • [Cites] J Postgrad Med. 1995 Jul-Sep;41(3):83-4 [10707722.001]
  • [Cites] Pathology. 1999 Nov;31(4):373-8 [10643009.001]
  • [Cites] Endocrinology. 1994 Jun;134(6):2416-23 [8194468.001]
  • [Cites] J Clin Invest. 1994 May;93(5):1959-67 [8182127.001]
  • [Cites] Cancer. 1995 Mar 1;75(5):1094-9 [7850706.001]
  • [Cites] Lab Invest. 1994 Oct;71(4):465-71 [7526033.001]
  • [Cites] Nihon Seikeigeka Gakkai Zasshi. 1994 May;68(5):407-14 [7914219.001]
  • [Cites] Am J Pathol. 1994 Oct;145(4):856-67 [7943176.001]
  • [Cites] Br J Oral Maxillofac Surg. 1993 Apr;31(2):89-94 [8471587.001]
  • [Cites] J Cancer Res Clin Oncol. 1993;119(5):301-3 [8440744.001]
  • [Cites] J Cell Sci. 1992 Mar;101 ( Pt 3):681-6 [1522150.001]
  • [Cites] Lab Invest. 1992 Aug;67(2):166-74 [1501443.001]
  • [Cites] J Clin Pathol. 1992 May;45(5):398-404 [1597517.001]
  • [Cites] Br J Cancer. 1992 Apr;65(4):523-6 [1562461.001]
  • [Cites] Endocr Rev. 1992 Feb;13(1):66-80 [1555533.001]
  • [Cites] Endocrinology. 1991 May;128(5):2324-35 [1850350.001]
  • [Cites] Endocrinol Jpn. 1990 Oct;37(5):741-7 [2086204.001]
  • [Cites] Acta Cytol. 1990 Nov-Dec;34(6):863-7 [2256421.001]
  • [Cites] Endocrinology. 1989 Jul;125(1):20-7 [2544401.001]
  • [Cites] Clin Orthop Relat Res. 1986 Mar;(204):59-75 [3006962.001]
  • [Cites] Nature. 1961 Apr 29;190:459-60 [13777407.001]
  • [Cites] Endocrinology. 1998 Oct;139(10):4353-63 [9751519.001]
  • [Cites] J Cell Biochem. 1998 Jul 1;70(1):121-9 [9632113.001]
  • [Cites] J Oral Maxillofac Surg. 1997 Dec;55(12 Suppl 5):38-45 [9393425.001]
  • [Cites] J Pathol. 1985 Apr;145(4):297-305 [2987469.001]
  • [Cites] J Pathol. 1987 Oct;153(2):121-6 [2961857.001]
  • [Cites] Cell Tissue Res. 1985;241(3):671-5 [2992797.001]
  • [Cites] Cancer. 1988 Sep 15;62(6):1139-45 [2457425.001]
  • [Cites] Recent Prog Horm Res. 1989;45:507-27; discussion 527-31 [2682847.001]
  • [Cites] Endocrinology. 1988 Apr;122(4):1373-82 [3345718.001]
  • [Cites] Veroff Pathol. 1984;122:1-195 [6091360.001]
  • [Cites] Cancer Res. 1987 Aug 1;47(15):4141-5 [3300960.001]
  • [Cites] J Pathol. 1984 Dec;144(4):281-94 [6520652.001]
  • [Cites] J Cell Sci. 1984 Aug;70:61-71 [6501437.001]
  • [Cites] J Interferon Res. 1987 Oct;7(5):619-26 [3479501.001]
  • [Cites] J Oral Maxillofac Surg. 1986 Sep;44(9):708-13 [3462363.001]
  • [Cites] Endocrinology. 1986 Feb;118(2):824-8 [3455914.001]
  • [Cites] Am J Pathol. 1986 Feb;122(2):363-78 [3946557.001]
  • [Cites] J Bone Joint Surg Am. 1990 Feb;72(2):252-8 [1968067.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Sep;87(18):7260-4 [2169622.001]
  • [Cites] Endocrinology. 1990 Jun;126(6):3153-8 [2161750.001]
  • [Cites] Endocrinology. 1990 May;126(5):2733-41 [2184023.001]
  • [Cites] Cancer. 1990 Jun 15;65(12):2697-703 [2340469.001]
  • [Cites] Science. 1980 May 2;208(4443):516-8 [6154315.001]
  • [Cites] Int J Oral Surg. 1984 Apr;13(2):92-100 [6430822.001]
  • [Cites] Pathol Res Pract. 1984 May;178(5):431-40 [6462948.001]
  • [Cites] Calcif Tissue Int. 1980;31(1):29-34 [6770971.001]
  • [Cites] Pathol Res Pract. 1999;195(11):753-7 [10605695.001]
  • [Cites] Ann Surg Oncol. 2007 Oct;14(10):2896-902 [17653593.001]
  • [Cites] Bosn J Basic Med Sci. 2007 Feb;7(1):58-65 [17489771.001]
  • [Cites] Fetal Pediatr Pathol. 2006 Sep-Oct;25(5):241-8 [17438664.001]
  • [Cites] Int Orthop. 2006 Dec;30(6):484-9 [17013643.001]
  • [Cites] J Bone Miner Res. 2006 Sep;21(9):1339-49 [16939392.001]
  • [Cites] Ultrastruct Pathol. 2006 May-Jun;30(3):151-8 [16825116.001]
  • [Cites] Pediatr Dev Pathol. 2006 Jan-Feb;9(1):38-43 [16808643.001]
  • [Cites] Oncol Rep. 2006 Mar;15(3):589-94 [16465417.001]
  • [Cites] Hum Pathol. 2005 Sep;36(9):945-54 [16153456.001]
  • [Cites] Clin Orthop Relat Res. 2005 Sep;438:116-22 [16131879.001]
  • [Cites] Am J Pathol. 2005 Jul;167(1):117-28 [15972958.001]
  • [Cites] Cancer Genet Cytogenet. 2005 May;159(1):32-6 [15860354.001]
  • [Cites] J Assoc Physicians India. 2004 Jul;52:585-6 [15645990.001]
  • [Cites] J Orthop Res. 2005 Jan;23(1):203-9 [15607894.001]
  • [Cites] Clin Orthop Relat Res. 1997 May;(338):205-14 [9170381.001]
  • [Cites] Ann Rheum Dis. 1996 Jun;55(6):388-95 [8694579.001]
  • [Cites] Cancer Genet Cytogenet. 1996 May;88(1):35-8 [8630976.001]
  • [Cites] Bone. 1995 Aug;17(2 Suppl):87S-91S [8579904.001]
  • [Cites] N Engl J Med. 1995 Dec 28;333(26):1757-63 [7491141.001]
  • [Cites] Clin Orthop Relat Res. 1976 Oct;(120):201-31 [975659.001]
  • [Cites] N Engl J Med. 1974 Nov 14;291(20):1041-6 [4413338.001]
  • [Cites] Science. 1973 May 25;180(4088):875 [4706681.001]
  • [Cites] Science. 1975 Nov 21;190(4216):784-5 [1105786.001]
  • [Cites] J Exp Med. 1975 Sep 1;142(3):651-63 [1100763.001]
  • [Cites] J Bone Joint Surg Am. 1976 Jul;58(5):612-8 [932060.001]
  • [Cites] Nature. 1975 Nov 27;258(5533):325-7 [1196357.001]
  • [Cites] J Endocrinol. 1969 Nov;45(3):387-400 [5358264.001]
  • [Cites] J Pathol Bacteriol. 1966 Jul;92(1):163-7 [5956253.001]
  • [Cites] Am J Pathol. 2004 Nov;165(5):1773-80 [15509545.001]
  • [Cites] Mund Kiefer Gesichtschir. 2004 Sep;8(5):316-21 [15480872.001]
  • [Cites] Hand Clin. 2004 Aug;20(3):269-81, vi [15275686.001]
  • [Cites] Mod Pathol. 2004 May;17(5):518-25 [15044915.001]
  • [Cites] Hum Pathol. 2003 Oct;34(10):983-93 [14608531.001]
  • [Cites] Diagn Cytopathol. 2004 Jan;30(1):14-8 [14696139.001]
  • [Cites] Pathobiology. 2002-2003;70(6):333-42 [12865629.001]
  • [Cites] Life Sci. 2003 Aug 1;73(11):1427-36 [12850503.001]
  • (PMID = 18787633.001).
  • [ISSN] 1936-2625
  • [Journal-full-title] International journal of clinical and experimental pathology
  • [ISO-abbreviation] Int J Clin Exp Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2480584
  • [Keywords] NOTNLM ; Giant cell tumor / aneurysmal bone cyst / bone / bone matrix / hemorrhage / osteoclast / osteoclastoma / telomerase
  •  go-up   go-down


51. Behzatoğlu K, Durak H, Canberk S, Aydin O, Huq GE, Oznur M, Ozyalvaçli G, Yildiz P: Giant cell tumor-like lesion of the urinary bladder: a report of two cases and literature review; giant cell tumor or undifferentiated carcinoma? Diagn Pathol; 2009;4:48

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant cell tumor-like lesion of the urinary bladder: a report of two cases and literature review; giant cell tumor or undifferentiated carcinoma?
  • Giant cell tumor, excluding its prototype in bone, is usually a benign but local aggressive neoplasm originating from tendon sheath or soft tissue.
  • Giant cell tumors in visceral organs usually accompany epithelial tumors and the clinical behavior of giant cell tumor in urinary bladder is similar to its bone counterpart.
  • Here, we report two cases of giant cell tumor located in urinary bladder in comparison with nine reported cases in the English literature.
  • One of the two cases we present had no concurrent urothelial tumor at the time of diagnosis but had a history of a low grade noninvasive urothelial carcinoma with three recurrences.
  • The histology of these two cases was similar to the giant cell tumor of bone and composed of oval to spindle mononuclear cells with evenly spaced osteoclast-like giant cells.
  • Immunohistochemically, the giant cells showed staining with osteoclastic markers including CD68, TRAP, and LCA.
  • The histologic and immunohistochemical properties in our cases as well as their clinical courses were consistent with a giant cell tumor.
  • Consequently, tumors in urinary bladder showing features of giant cell tumor of bone may also be considered and termed "giant cell tumor".

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1998 Apr 1;82(7):1279-87 [9529019.001]
  • [Cites] J Urol. 2002 Apr;167(4):1784 [11912413.001]
  • [Cites] J Orthop Sci. 2005 Nov;10(6):581-8 [16307183.001]
  • [Cites] Mod Pathol. 2006 Feb;19(2):161-71 [16322750.001]
  • [Cites] Am J Surg Pathol. 2006 Apr;30(4):495-500 [16625096.001]
  • [Cites] Eur Arch Otorhinolaryngol. 2007 Feb;264(2):205-8 [16977452.001]
  • [Cites] Mod Pathol. 2001 Dec;14(12):1209-15 [11743042.001]
  • [Cites] Am J Surg Pathol. 2002 Nov;26(11):1467-76 [12409723.001]
  • [Cites] Pathol Int. 2003 Jul;53(7):450-6 [12828610.001]
  • [Cites] Arch Pathol Lab Med. 2004 Apr;128(4):440-3 [15043462.001]
  • [Cites] BMC Urol. 2004 Jun 18;4:7 [15207006.001]
  • [Cites] Am J Surg Pathol. 2004 Jul;28(7):953-61 [15223968.001]
  • [Cites] Cancer. 1973 Mar;31(3):621-5 [4693590.001]
  • [Cites] Am J Clin Pathol. 1984 May;81(5):666-75 [6326564.001]
  • [Cites] J Urol. 1985 Mar;133(3):472-5 [3974000.001]
  • [Cites] J Urol. 1989 Jul;142(1):120-2 [2733086.001]
  • [Cites] Arch Pathol Lab Med. 1987 Jan;111(1):43-8 [2432851.001]
  • [Cites] Am J Surg Pathol. 1991 Feb;15(2):160-8 [1989464.001]
  • [Cites] Histopathology. 1990 Nov;17(5):413-8 [1706298.001]
  • [Cites] J Oral Pathol Med. 1999 Feb;28(2):54-8 [9950250.001]
  • (PMID = 20043822.001).
  • [ISSN] 1746-1596
  • [Journal-full-title] Diagnostic pathology
  • [ISO-abbreviation] Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2811699
  •  go-up   go-down


52. Moskovszky L, Dezsö K, Athanasou N, Szendröi M, Kopper L, Kliskey K, Picci P, Sápi Z: Centrosome abnormalities in giant cell tumour of bone: possible association with chromosomal instability. Mod Pathol; 2010 Mar;23(3):359-66
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Centrosome abnormalities in giant cell tumour of bone: possible association with chromosomal instability.
  • Giant cell tumour of bone, a benign but potentially aggressive neoplasm, shows an increasing rate of chromosomal aneusomy that correlates with clinical course.
  • Mechanisms that generate chromosomal instability in giant cell tumour of bone are poorly understood.
  • To gain an insight into the possible mechanism for the generation of chromosomal instability in giant cell tumour of bone, we analysed 100 cases, including 57 primary nonrecurrent, 35 recurrent and 8 malignant giant cell tumour of bone cases. gamma-Tubulin immunohistochemistry was performed on tissue microarrays of 59 formalin-fixed paraffin-embedded cases, whereas pericentrin and gamma-tubulin fluorescent immunocytochemistry was carried out on 41 frozen smears.
  • Centrosome amplification was significantly higher in recurrent and malignant giant cell tumour of bones compared with nonrecurrent tumours (P<0.001).
  • These findings indicate that centrosome alteration and frequency of aneusomy correlate with clinical behaviour; the lack of an association between centrosome amplification and chromosome number alteration suggests that alternative causative mechanisms produce genetic instability in giant cell tumour of bone.
  • [MeSH-major] Bone Neoplasms / genetics. Centrosome / pathology. Chromosomal Instability. Giant Cell Tumor of Bone / genetics

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20062006.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens; 0 / Tubulin; 0 / pericentrin
  •  go-up   go-down


53. Dudko S, Kusz D, Cieliński L, Nowak M: The application of bone cement to fill the surgical defect after resection of a giant-cell tumor: A case report. Ortop Traumatol Rehabil; 2005 Oct 30;7(5):563-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The application of bone cement to fill the surgical defect after resection of a giant-cell tumor: A case report.
  • Background. A case of a large bone defect treated with bone cement filler is discussed, and the usefulness and advantages of this treatment method are assessed. Case report.
  • A 25-year-old male was admitted to our hospital with an intra-articular pathological fracture of the lateral femoral condyle due to an underlying giant cell tumor (stage I according to the Enneking classification).
  • The tumor was surgically resected, and the walls of the post-operative bone defect were treated with a burr.
  • The defect was then filled with bone cement (PMMA).
  • The tumor was found to be histologically benign.
  • Post-surgical treatment included immobilization in a cylinder cast and no weight bearing for a period of 8 weeks.
  • The follow-up period was 7 years, during which time no clinical or radiological signs of tumor recurrence were found.
  • There was visible osteosclerosis surrounding the bone cement filler, which is believed to be a prognostically favorable finding, associated with a low risk of recurrence.
  • Conclusions. The use of bone cement in order to fill a bone defect after tumor excision proved to be an effective and safe method to manage a giant-cell tumor of the bone.
  • This method provided good biomechanical circumstances and allowed for good follow-up, as it enabled easy detection of possible tumor recurrence.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17611450.001).
  • [ISSN] 1509-3492
  • [Journal-full-title] Ortopedia, traumatologia, rehabilitacja
  • [ISO-abbreviation] Ortop Traumatol Rehabil
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


54. Dominkus M, Ruggieri P, Bertoni F, Briccoli A, Picci P, Rocca M, Mercuri M: Histologically verified lung metastases in benign giant cell tumours--14 cases from a single institution. Int Orthop; 2006 Dec;30(6):499-504
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histologically verified lung metastases in benign giant cell tumours--14 cases from a single institution.
  • From 1975 to 1997, 649 cases of benign giant cell tumours of the bone were treated at the Istituto Rizzoli.
  • The time interval between the diagnosis and the appearance of the lung metastases ranged from 3 months to 11.9 years.
  • Histologically, the metastases were identical to the primary bone lesions.
  • Local recurrence of the bone lesion occurred in seven patients before or simultaneously to the metastases.
  • In contrast to previous reports, we could not detect a predominance of the distal radius, but all of the patients had a stage III tumour according to the Enneking criteria of benign lesions.
  • We conclude that even metastatic benign giant cell tumours have an excellent prognosis after adequate resection.
  • [MeSH-major] Bone Neoplasms / pathology. Giant Cell Tumor of Bone / secondary. Lung Neoplasms / secondary. Neoplasm Recurrence, Local / pathology

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Orthop Surg (Hong Kong). 2004 Jun;12(1):55-62 [15237123.001]
  • [Cites] J Bone Joint Surg Am. 1959 Jul;41-A(5):895-904 [13664723.001]
  • [Cites] Ann Thorac Surg. 1973 Nov;16(5):531-5 [4746080.001]
  • [Cites] Cancer. 1980 Oct 1;46(7):1641-9 [7417958.001]
  • [Cites] J Bone Joint Surg Am. 1984 Feb;66(2):269-74 [6693454.001]
  • [Cites] Cancer. 1984 Dec 1;54(11):2564-7 [6498747.001]
  • [Cites] J Bone Joint Surg Am. 1987 Jan;69(1):106-14 [3805057.001]
  • [Cites] N Engl J Med. 1988 Feb 25;318(8):517 [3340133.001]
  • [Cites] Clin Orthop Relat Res. 1988 Dec;(237):275-85 [3056645.001]
  • [Cites] J Bone Joint Surg Br. 1989 May;71(3):432-3 [2722935.001]
  • [Cites] AJR Am J Roentgenol. 1992 Feb;158(2):331-4 [1729794.001]
  • [Cites] Clin Orthop Relat Res. 1994 May;(302):219-30 [8168305.001]
  • [Cites] J Bone Joint Surg Am. 1996 Jan;78(1):106-10 [8550667.001]
  • [Cites] J Bone Joint Surg Br. 1998 Jan;80(1):43-7 [9460951.001]
  • [Cites] J Bone Joint Surg Br. 1957 May;39-B(2):346-57 [13438979.001]
  • [Cites] J Bone Joint Surg Am. 1970 Jun;52(4):619-64 [5479455.001]
  • (PMID = 16909252.001).
  • [ISSN] 0341-2695
  • [Journal-full-title] International orthopaedics
  • [ISO-abbreviation] Int Orthop
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Other-IDs] NLM/ PMC3172731
  •  go-up   go-down


55. Dhillon MS, Prasad P: Multicentric giant cell tumour of bone. Acta Orthop Belg; 2007 Jun;73(3):289-99
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multicentric giant cell tumour of bone.
  • Although giant cell tumour (GCT) is seen quite frequently, multicentric giant cell tumour (MCGCT) is a rare entity occurring in less than 1% of patients with GCT.
  • The pathogenesis of MCGCT is debated; various mechanisms have been postulated, including contiguous spread, iatrogenic tumour cell seeding, benign metastasis, malignant transformation and de novo formation.
  • Individual lesions in a patient with MCGCT are radiologically and histologically indistinguishable from the solitary GCT.
  • [MeSH-major] Bone Neoplasms. Giant Cell Tumor of Bone

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17715717.001).
  • [ISSN] 0001-6462
  • [Journal-full-title] Acta orthopaedica Belgica
  • [ISO-abbreviation] Acta Orthop Belg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Belgium
  • [Number-of-references] 77
  •  go-up   go-down


56. Lee CH, Espinosa I, Jensen KC, Subramanian S, Zhu SX, Varma S, Montgomery KD, Nielsen TO, van de Rijn M, West RB: Gene expression profiling identifies p63 as a diagnostic marker for giant cell tumor of the bone. Mod Pathol; 2008 May;21(5):531-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene expression profiling identifies p63 as a diagnostic marker for giant cell tumor of the bone.
  • Giant cell tumor of the bone (GCTOB) is a primary bone tumor that occurs mainly in young adults and is capable of locally aggressive growth.
  • Its histologic appearance can resemble a number of benign and malignant tumors but no useful diagnostic marker is known currently.
  • To identify diagnostic markers for this tumor, global gene expression profiling using cDNA microarray was performed on 6 fresh-frozen GCTOB, 3 aneurysmal bone cysts, 4 fibrous dysplasias and 12 giant cell tumors of tendon sheath/diffuse-type giant cell tumors.
  • The diagnostic utility of p63 was subsequently confirmed using anti-p63 antibody on a series of 26 GCTOB, 25 aneurysmal bone cysts, 15 chondroblastomas, 13 giant cell reparative granulomas, 13 chondromyxoid fibromas, 4 brown tumors, 4 fibrous dysplasias, 53 giant cell tumors of tendon sheath/diffuse-type giant cell tumors and 385 additional mesenchymal tumors in tissue microarrays.
  • Strong p63 nuclear staining was present in 18 of 26 (69%) GCTOB, 3 of 15 (20%) chondroblastomas and in 1 of 25 (4%) aneurysmal bone cysts while none of the other tumors commonly considered in the differential diagnosis of GCTOB showed any detectable p63 staining.
  • Strong p63 staining is rare in bone and soft-tissue tumors in general.
  • These findings altogether show that p63 can be used as a diagnostic marker to aid the clinical diagnosis of GCTOB.
  • [MeSH-major] Biomarkers, Tumor / genetics. Bone Neoplasms / genetics. Gene Expression Profiling. Giant Cell Tumor of Bone / genetics. Membrane Proteins / genetics
  • [MeSH-minor] Adult. Bone Cysts, Aneurysmal / pathology. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Male. Middle Aged. Oligonucleotide Array Sequence Analysis. Sarcoma / pathology

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18192965.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CKAP4 protein, human; 0 / Membrane Proteins
  •  go-up   go-down


57. Tse LF, Wong KC, Kumta SM, Huang L, Chow TC, Griffith JF: Bisphosphonates reduce local recurrence in extremity giant cell tumor of bone: a case-control study. Bone; 2008 Jan;42(1):68-73
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bisphosphonates reduce local recurrence in extremity giant cell tumor of bone: a case-control study.
  • BACKGROUND: Giant cell tumor (GCT) of bone is a benign but locally aggressive tumor that is characterized by the presence of mononuclear stromal cells and multinucleated giant cells.
  • Although topical adjuvants have been used in the past, local recurrence following intralesional excision of GCT of bone continues to remain a problem.
  • The use of bisphosphonates as an anti-osteoclastic agent in the management of osteolytic bone metastases is well accepted.
  • Therefore our clinical study aims to investigate whether the administration of bisphosphonate as an adjuvant can further decrease local recurrence following the surgical treatment of GCT of bone.
  • CONCLUSION: Clinical use of bisphosphonates as an adjuvant therapy for giant cell tumor of bone demonstrated a lower local recurrence rate.
  • [MeSH-major] Bone Neoplasms. Diphosphonates / pharmacology. Extremities / pathology. Giant Cell Tumor of Bone. Neoplasm Recurrence, Local / prevention & control

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17962092.001).
  • [ISSN] 8756-3282
  • [Journal-full-title] Bone
  • [ISO-abbreviation] Bone
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Diphosphonates
  •  go-up   go-down


58. Hashimoto K, Hatori M, Hosaka M, Watanabe M, Hasegawa T, Kokubun S: Osteosarcoma arising from giant cell tumor of bone ten years after primary surgery: a case report and review of the literature. Tohoku J Exp Med; 2006 Feb;208(2):157-62
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Osteosarcoma arising from giant cell tumor of bone ten years after primary surgery: a case report and review of the literature.
  • Giant cell tumor of the bone (GCT) is a relatively uncommon tumor.
  • It is characterized by the presence of multinucleated giant cells.
  • GCT is a primary benign tumor but may evolve into a malignant tumor, usually after irradiation.
  • Roentgenogram revealed a bone tumor in the lateral femoral condyle of the right knee.
  • Histopathological examination demonstrated the features of GCT, and treatment consisted of curettage and bone grafting.
  • However, given the aggressiveness of the malignant tumor, this is unlikely.
  • The recurrence of pain and aggravation of bone destruction many years after the primary treatment suggest malignant transformation of GCT.
  • [MeSH-major] Bone Neoplasms / complications. Giant Cell Tumors / complications. Neoplasms, Second Primary. Osteosarcoma / etiology

  • Genetic Alliance. consumer health - Osteosarcoma.
  • Genetic Alliance. consumer health - TEN.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16434839.001).
  • [ISSN] 0040-8727
  • [Journal-full-title] The Tohoku journal of experimental medicine
  • [ISO-abbreviation] Tohoku J. Exp. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


59. Matsuo T, Hiyama E, Sugita T, Shimose S, Kubo T, Mochizuki Y, Adachi N, Kojima K, Sharman P, Ochi M: Telomerase activity in giant cell tumors of bone. Ann Surg Oncol; 2007 Oct;14(10):2896-902
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Telomerase activity in giant cell tumors of bone.
  • BACKGROUND: A giant cell tumor of bone (GCT) is a histologically benign neoplasma that has an unpredictable pattern of biological aggressiveness.
  • Telomerase activity was detected in 81% of tumor samples.
  • CONCLUSIONS: These results suggest that telomere length correlates with roentgenographic grade as a result of the frequency of cell division, and high telomerase activity indicates the aggressiveness of GCTs.
  • [MeSH-major] Bone Neoplasms / genetics. Giant Cell Tumor of Bone / genetics. Telomerase / genetics
  • [MeSH-minor] Adolescent. Adult. Blotting, Southern. Bone and Bones / pathology. Bone and Bones / surgery. Extremities / surgery. Female. Femoral Neoplasms / genetics. Femoral Neoplasms / pathology. Femoral Neoplasms / surgery. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / genetics. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Neoplasm Staging. Polymerase Chain Reaction. Polymorphism, Restriction Fragment Length / genetics. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17653593.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.7.49 / TERT protein, human; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


60. Liu H, Sun J, Wang Y, Yang X, Zhu E: [Repairing bone defects of benign bone neoplasm by grafting of bioactive glass combined with autologous bone marrow]. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2008 Nov;22(11):1349-53
MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Repairing bone defects of benign bone neoplasm by grafting of bioactive glass combined with autologous bone marrow].
  • OBJECTIVE: To investigate the clinical application of grafting with bioactive glass (BG) and autologous bone marrow for defect after resection and curettage of benign bone neoplasm.
  • METHODS: From January 2004 to May 2007, 34 patients with bone defects were repaired.
  • There were 14 cases of simple bone cysts, 6 cases of fibrous dysplasia, 3 cases of osteoid osteoma, 4 cases of non-ossifying fibroma, 2 cases of enchondroma and 3 cases of giant cell tumor of bone.
  • Tumor sizes varied from 2.0 cm x 1.5 cm x 1.0 cm to 9.0 cm x 3.0 cm x 2.5 cm.
  • Benign bone neoplasm was removed thoroughly with a curet or osteotome, bone defects ranged from 3.0 cm x 2.0 cm x 1.5 cm to 11.0 cm x 3.5 cm x 3.0 cm, which was closed-up with the mixtures of BG and autogenous red bone marrow.
  • The postoperative systemic and local reactions were observed, and the regular X-ray examinations were performed to observe the bone healing.
  • At averaged 16 weeks after operation, patients with bone tumor in lower limbs resumed walking independently and those with bone tumor in upper limbs resumed holding object.
  • There was no tumor recurrence during follow-up.
  • Radiographically, the interface between the implanted bone and host bone became fuzzy 1 month after implantation.
  • Two months after operation, the BG was absorbed gradually, new bone formation could be seen in the defects.
  • Four months after operation, implanted bone and host bone merged together, bone density increased.
  • Six to ten months after operation, the majority of the implanted BG was absorbed and substituted for new bone, bone remodeling was established.
  • CONCLUSION: BG may boast both bone conductive and bone inductive activities.
  • The combined grafting with BG and autologous bone marrow appears to be minimally invasive treatment to repair bone defects of benign bone neoplasm, with rare complications and no significant reverse reaction, and could repair bone defects completely.
  • [MeSH-major] Bone Marrow Transplantation. Bone Substitutes. Postoperative Complications / surgery. Reconstructive Surgical Procedures / methods
  • [MeSH-minor] Adolescent. Adult. Bone Neoplasms / surgery. Bone and Bones / pathology. Child. Female. Follow-Up Studies. Glass. Humans. Male. Middle Aged. Transplantation, Autologous

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19068605.001).
  • [ISSN] 1002-1892
  • [Journal-full-title] Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery
  • [ISO-abbreviation] Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Bone Substitutes
  •  go-up   go-down


61. Rodrigues LM, Nicolau RJ, Puertas EB, Milani C: Vertebrectomy of giant cell tumor with vertebral artery embolization: case report. J Pediatr Orthop B; 2009 Mar;18(2):99-102
MedlinePlus Health Information. consumer health - Neck Injuries and Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vertebrectomy of giant cell tumor with vertebral artery embolization: case report.
  • Giant cell tumors (GCT) are rare in the cervical spine in adolescent children.
  • This tumor is histologically benign, but there is a high recurrence rate.
  • The authors describe a case of a patient of adolescent age with a GCT in the cervical spine.
  • It was necessary to study the embolization of the vertebral artery to planning the vertebrectomy surgery for resection of the entire tumor to avoid recurrence.
  • The resection of the tumor was carried out by combined access (anteriorly and posteriorly) and was stabilized with plate, posterior lateral mass screws, and autologous iliac crest graft.
  • [MeSH-major] Cervical Vertebrae / surgery. Embolization, Therapeutic / methods. Giant Cell Tumor of Bone / therapy. Spinal Neoplasms / therapy. Vertebral Artery
  • [MeSH-minor] Adolescent. Bone Plates. Bone Screws. Bone Transplantation. Female. Humans. Ilium / transplantation. Prostheses and Implants. Spinal Fusion / instrumentation. Spinal Fusion / methods. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19276993.001).
  • [ISSN] 1473-5865
  • [Journal-full-title] Journal of pediatric orthopedics. Part B
  • [ISO-abbreviation] J Pediatr Orthop B
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


62. Li JM, Yang ZP, Li ZF, Li X, Carter SR: Knee reconstruction with preservation of the meniscus in tibial giant cell tumor. Clin Orthop Relat Res; 2008 Dec;466(12):3101-7
MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Knee reconstruction with preservation of the meniscus in tibial giant cell tumor.
  • Giant cell tumor of bone sometimes is an aggressive benign skeletal tumor.
  • Historically, curettage and bone grafting have a high recurrence with satisfactory function whereas wide resection has a reduced recurrence rate with compromise of limb function.
  • We developed a method for achieving both goals for giant cell tumors located in only one lateral plateau of the proximal tibia.
  • We reconstructed 13 knees preserving the meniscus and reconstructing the tibial plateau with an iliac plate autograft after resection of a giant cell tumor involving one tibial plateau.
  • While resecting the tumor, the normal anatomic structures of the knee can be preserved or restored in many patients.
  • [MeSH-major] Bone Neoplasms / surgery. Giant Cell Tumor of Bone / surgery. Orthopedic Procedures / methods. Reconstructive Surgical Procedures / methods
  • [MeSH-minor] Adult. Bone Transplantation. Female. Humans. Ilium / transplantation. Male. Menisci, Tibial. Middle Aged. Neoplasm Recurrence, Local / epidemiology. Retrospective Studies. Tibia. Transplantation, Autologous. Young Adult

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Orthop Relat Res. 2002 Apr;(397):248-58 [11953616.001]
  • [Cites] Clin Orthop Relat Res. 2005 Jun;(435):211-8 [15930941.001]
  • [Cites] J Bone Joint Surg Br. 2004 Mar;86(2):212-6 [15046435.001]
  • [Cites] J Bone Joint Surg Am. 1970 Jun;52(4):619-64 [5479455.001]
  • [Cites] J Bone Joint Surg Am. 1975 Mar;57(2):167-73 [1112843.001]
  • [Cites] J Bone Joint Surg Am. 1982 Jun;64(5):755-61 [7045129.001]
  • [Cites] Acta Orthop Scand. 1984 Apr;55(2):209-14 [6369866.001]
  • [Cites] J Bone Joint Surg Am. 1986 Feb;68(2):235-42 [3511063.001]
  • [Cites] Clin Orthop Relat Res. 1986 Mar;(204):45-58 [3514036.001]
  • [Cites] J Bone Joint Surg Am. 1987 Jan;69(1):106-14 [3805057.001]
  • [Cites] Clin Orthop Relat Res. 1993 Jan;(286):241-6 [8425352.001]
  • [Cites] J Bone Joint Surg Am. 1993 Nov;75(11):1648-55 [8245057.001]
  • [Cites] J Bone Joint Surg Am. 1993 Nov;75(11):1656-62 [8245058.001]
  • [Cites] Changgeng Yi Xue Za Zhi. 1998 Mar;21(1):37-43 [9607262.001]
  • [Cites] Clin Orthop Relat Res. 1999 Feb;(359):176-88 [10078141.001]
  • [Cites] J Bone Joint Surg Am. 1999 Jun;81(6):811-20 [10391546.001]
  • [Cites] Clin Orthop Relat Res. 2002 Apr;(397):259-70 [11953617.001]
  • (PMID = 18830792.001).
  • [ISSN] 1528-1132
  • [Journal-full-title] Clinical orthopaedics and related research
  • [ISO-abbreviation] Clin. Orthop. Relat. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2628220
  •  go-up   go-down


63. Kumar A, Varshney MK, Trikha V, Rastogi S: An unusual presentation of a rare chest wall tumour: giant cell tumour of bone. Joint Bone Spine; 2007 Jan;74(1):100-2
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An unusual presentation of a rare chest wall tumour: giant cell tumour of bone.
  • Giant cell tumour of bone is an aggressive benign bone tumour.
  • We report a case of giant cell tumour of the anterior end of the rib masquerading as a sub-mammary abscess in lactating women.
  • [MeSH-major] Bone Neoplasms / diagnosis. Giant Cell Tumor of Bone / diagnosis. Thoracic Wall
  • [MeSH-minor] Abscess / diagnosis. Adult. Diagnosis, Differential. Female. Humans. Lactation. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17197221.001).
  • [ISSN] 1778-7254
  • [Journal-full-title] Joint, bone, spine : revue du rhumatisme
  • [ISO-abbreviation] Joint Bone Spine
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] France
  •  go-up   go-down


64. Chekrine T, Tawfiq N, Bourhaleb Z, Benchakroun N, Jouhadi H, Sahraoui S, Benider A: [Giant-cell bone tumors of the spine: report of two cases and literature review]. Cancer Radiother; 2009 Sep;13(5):451-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Giant-cell bone tumors of the spine: report of two cases and literature review].
  • [Transliterated title] Deux cas de tumeurs osseuses à cellules géantes du rachis et revue de la littérature.
  • Giant cell tumours (GCT) are relatively rare neoplasms, most often benign.
  • We report two observations of GCT, the spine in a 51-year-old woman and a 14-year-old boy.
  • The diagnosis was confirmed by histological examination in two cases.
  • [MeSH-major] Giant Cell Tumor of Bone / radiotherapy. Spinal Neoplasms / radiotherapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19615930.001).
  • [ISSN] 1769-6658
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 15
  •  go-up   go-down


65. Bayar MA, Erdem Y, Gokcek C, Koktekir E, Kilic C, Yasitli U, Tekiner A: Giant cell reparative granuloma of the axis. Turk Neurosurg; 2009 Oct;19(4):423-7
MedlinePlus Health Information. consumer health - Spine Injuries and Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant cell reparative granuloma of the axis.
  • Giant cell reparative granuloma (GCRG) is a rare, benign fibroosseous lesion.
  • Histopathological diagnosis was GCRG.
  • We filled the tumor cavity with a bone graft and the patient was discharged with a halo brace without any neurological deficits.
  • The follow-up CT revealed one year after the surgery showed sclerosis at the tumor site.
  • The etiopathogenesis of GCRG is still controversial and the differential diagnosis, especially from giant cell tumor of bone is quite difficult.
  • [MeSH-major] Axis, Cervical Vertebra / pathology. Granuloma, Giant Cell / pathology. Magnetic Resonance Imaging. Spinal Diseases / pathology

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19847766.001).
  • [ISSN] 1019-5149
  • [Journal-full-title] Turkish neurosurgery
  • [ISO-abbreviation] Turk Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Turkey
  •  go-up   go-down


66. Refai D, Dunn GP, Santiago P: Giant cell tumor of the thoracic spine: case report and review of the literature. Surg Neurol; 2009 Feb;71(2):228-33; discussion 233

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant cell tumor of the thoracic spine: case report and review of the literature.
  • BACKGROUND: Giant cell tumors are benign tumors of the bone that most commonly occur at the ends of the long bones; they are rarely found in the spine above the sacrum.
  • The management of patients with giant cell tumors of the spine represents a challenge, and the clinical approach to this problem continues to evolve with improvements in surgical and adjunctive therapies.
  • CASE DESCRIPTION: A 19-year-old woman with localized back pain and a spinal compression deformity was found to harbor a giant cell tumor of the T7 vertebral body.
  • To optimize local disease control, the patient underwent IMRT delivered to the site of tumor resection.
  • CONCLUSION: The literature and approaches to the management of spinal giant cell tumors are reviewed.
  • [MeSH-major] Giant Cell Tumor of Bone / diagnosis. Giant Cell Tumor of Bone / surgery. Spinal Neoplasms / diagnosis. Spinal Neoplasms / surgery. Thoracic Vertebrae

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18207522.001).
  • [ISSN] 0090-3019
  • [Journal-full-title] Surgical neurology
  • [ISO-abbreviation] Surg Neurol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 26
  •  go-up   go-down


67. Matsubayashi S, Nakashima M, Kumagai K, Egashira M, Naruke Y, Kondo H, Hayashi T, Shindo H: Immunohistochemical analyses of beta-catenin and cyclin D1 expression in giant cell tumor of bone (GCTB): a possible role of Wnt pathway in GCTB tumorigenesis. Pathol Res Pract; 2009;205(9):626-33
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical analyses of beta-catenin and cyclin D1 expression in giant cell tumor of bone (GCTB): a possible role of Wnt pathway in GCTB tumorigenesis.
  • Giant cell tumor of bone (GCTB) is a benign neoplasm but occasionally shows local recurrence, and histologically consists of osteoclast-like giant cells (GC) and stromal mononuclear cells (SC), which are capable of proliferation and osteoblastic differentiation.
  • Activation of Wnt signaling can induce osteoblast differentiation and osteoclastgenesis during bone resorption process.
  • Since cyclin D1 in GC was never associated with the expression of the well-known proliferative marker Ki-67, cyclin D1 expression might play a role in GC formation instead of promoting cell proliferation during GCTB tumorigenesis.
  • Importantly, it was suggested that the nuclear beta-catenin staining level might be associated with tumor recurrence in GCTB.
  • [MeSH-major] Bone Neoplasms / metabolism. Cyclin D1 / biosynthesis. Giant Cell Tumor of Bone / metabolism. Wnt Proteins / metabolism. beta Catenin / biosynthesis
  • [MeSH-minor] Adolescent. Adult. Cell Nucleus / metabolism. Female. Gene Expression. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Ki-67 Antigen / biosynthesis. Ki-67 Antigen / genetics. Male. Middle Aged. Neoplasm Recurrence, Local / metabolism. Signal Transduction / physiology. Young Adult

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19324500.001).
  • [ISSN] 1618-0631
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Wnt Proteins; 0 / beta Catenin; 136601-57-5 / Cyclin D1
  •  go-up   go-down


68. Sawyer JR, Goosen LS, Binz RL, Swanson CM, Nicholas RW: Evidence for telomeric fusions as a mechanism for recurring structural aberrations of chromosome 11 in giant cell tumor of bone. Cancer Genet Cytogenet; 2005 May;159(1):32-6
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evidence for telomeric fusions as a mechanism for recurring structural aberrations of chromosome 11 in giant cell tumor of bone.
  • Giant cell tumor of bone (GCTB) is a benign but often aggressive tumor with a tendency toward local recurrence.
  • A third tumor with clonal tas of 11pter showed 2 additional subclones, one with ring chromosome 11 and the other with an extra copy of 1q.
  • To our knowledge, the 2 cases with del(11)(p11) represent the first report of a recurring structural chromosome aberration in GCTB.
  • [MeSH-major] Bone Neoplasms / genetics. Chromosome Aberrations. Chromosomes, Human, Pair 11 / genetics. Giant Cell Tumors / genetics. Neoplasm Recurrence, Local / genetics. Telomere

  • Genetic Alliance. consumer health - Chromosome 11.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15860354.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


69. Cozzolino A, Balleri P, Ruggiero G, Veltri M: Use of short implants for functional restoration of the mandible after giant cell tumor removal. Case report. Minerva Stomatol; 2006 May;55(5):307-14

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of short implants for functional restoration of the mandible after giant cell tumor removal. Case report.
  • The giant cell tumor of the jaws is a rare benign lesion, it has a slow and progressive evolution and it is locally aggressive.
  • Diagnosis is made by radiological and histological examination and surgical treatment is necessary.
  • The clinical case of a 28-year-old man affected by a giant cell tumor of the mandible with an aggressive clinical and radiographical behaviour is reported.
  • The patient showed a jaw swelling covered by hyperemic fibro-mucous tissue from tooth 4.6 to 3.4, absence of cortical bone and mobility of teeth.
  • The giant cell tumor diagnosis was made with orthopantomography (OPT), computed tomography (CT) and needle biopsy.
  • The lesion was surgically removed and histological examination confirmed the diagnosis.
  • In spite of the wide loss of bony substance after surgery, the patient was provided with an implant supported fixed prosthesis without previous bone graft.
  • In this case short implants allowed the prosthetic rehabilitation of a mandible with severe ''resorption'' due to surgical removal of a tumor.
  • Implants were placed in the residual bone volume and successfully used to support a fixed prosthesis.
  • [MeSH-major] Dental Implantation, Endosseous. Dental Implants. Giant Cell Tumor of Bone / surgery. Mandibular Neoplasms / surgery
  • [MeSH-minor] Adult. Bone Resorption. Equipment Design. Humans. Male. Time Factors. Tooth Extraction. Wound Healing

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16688107.001).
  • [ISSN] 0026-4970
  • [Journal-full-title] Minerva stomatologica
  • [ISO-abbreviation] Minerva Stomatol
  • [Language] eng; ita
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Dental Implants
  •  go-up   go-down


70. Morgan T, Atkins GJ, Trivett MK, Johnson SA, Kansara M, Schlicht SL, Slavin JL, Simmons P, Dickinson I, Powell G, Choong PF, Holloway AJ, Thomas DM: Molecular profiling of giant cell tumor of bone and the osteoclastic localization of ligand for receptor activator of nuclear factor kappaB. Am J Pathol; 2005 Jul;167(1):117-28
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular profiling of giant cell tumor of bone and the osteoclastic localization of ligand for receptor activator of nuclear factor kappaB.
  • Giant cell tumor of bone (GCT) is a generally benign, osteolytic neoplasm comprising stromal cells and osteoclast-like giant cells.
  • The osteoclastic cells, which cause bony destruction, are thought to be recruited from normal monocytic pre-osteoclasts by stromal cell expression of the ligand for receptor activator of nuclear factor kappaB (RANKL).
  • Using expression profiling, we identified both osteoblast and osteoclast signatures within GCTs, including key regulators of osteoclast differentiation and function such as RANKL, a C-type lectin, osteoprotegerin, and the wnt inhibitor SFRP4.
  • [MeSH-major] Bone Neoplasms / genetics. Carrier Proteins / metabolism. Giant Cell Tumor of Bone / genetics. Membrane Glycoproteins / metabolism. Osteoclasts / metabolism
  • [MeSH-minor] Cell Differentiation / physiology. Cell Lineage. DNA Primers. Flow Cytometry. Gene Expression. Gene Expression Profiling. Histiocytoma, Benign Fibrous / genetics. Humans. Immunohistochemistry. Leiomyosarcoma / genetics. Liposarcoma / genetics. Nucleic Acid Hybridization. Proteins / analysis. RANK Ligand. RNA, Messenger / analysis. Receptor Activator of Nuclear Factor-kappa B. Reverse Transcriptase Polymerase Chain Reaction. Sarcoma, Synovial / genetics

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Bone. 1999 Nov;25(5):525-34 [10574572.001]
  • [Cites] Cancer Genet Cytogenet. 1993 Jul 1;68(1):1-21 [8330278.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Feb 15;97(4):1566-71 [10677500.001]
  • [Cites] Am J Pathol. 2000 Mar;156(3):761-7 [10702390.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Apr 21;270(3):1124-7 [10772961.001]
  • [Cites] J Bone Miner Res. 2000 Apr;15(4):640-9 [10780856.001]
  • [Cites] Endocr Rev. 2000 Aug;21(4):393-411 [10950158.001]
  • [Cites] Mod Pathol. 2000 Nov;13(11):1206-10 [11106078.001]
  • [Cites] Arthritis Res. 2000;2(6):451-456 [11094458.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 May 8;98(10):5798-803 [11331755.001]
  • [Cites] J Biol Chem. 2001 Mar 9;276(10):7376-82 [11084030.001]
  • [Cites] Nat Med. 2001 Jun;7(6):673-9 [11385503.001]
  • [Cites] Int J Cancer. 2001 Sep15;93(6):769-72 [11519035.001]
  • [Cites] J Bone Miner Res. 2001 Oct;16(10):1747-9 [11585336.001]
  • [Cites] Nat Genet. 2001 Nov;29(3):263-4 [11687795.001]
  • [Cites] Am J Clin Pathol. 2002 Feb;117(2):210-6 [11863217.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Apr 2;99(7):4477-82 [11930005.001]
  • [Cites] Lancet. 2002 Apr 13;359(9314):1301-7 [11965276.001]
  • [Cites] Nat Med. 2002 Sep;8(9):995-1003 [12185361.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Oct 1;99(20):12963-8 [12297621.001]
  • [Cites] Hum Pathol. 2003 Jan;34(1):65-73 [12605368.001]
  • [Cites] Nature. 2003 May 15;423(6937):337-42 [12748652.001]
  • [Cites] J Oral Pathol Med. 2003 Jul;32(6):367-75 [12787044.001]
  • [Cites] J Bone Miner Res. 2003 Jun;18(6):1088-98 [12817763.001]
  • [Cites] Am J Pathol. 2003 Aug;163(2):691-700 [12875988.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Aug 8;307(4):1051-8 [12878218.001]
  • [Cites] Gene. 2003 Oct 16;316:23-32 [14563548.001]
  • [Cites] FEBS Lett. 2003 Oct 23;553(3):257-61 [14572634.001]
  • [Cites] Hum Pathol. 2003 Oct;34(10):983-93 [14608531.001]
  • [Cites] N Engl J Med. 2003 Dec 25;349(26):2483-94 [14695408.001]
  • [Cites] Mol Endocrinol. 2004 May;18(5):1222-37 [14976225.001]
  • [Cites] Cancer Genet Cytogenet. 1993 Dec;71(2):132-8 [8281516.001]
  • [Cites] J Bone Miner Res. 1994 Jul;9(7):1013-20 [7942147.001]
  • [Cites] Bone. 1995 Aug;17(2):111-9 [8554918.001]
  • [Cites] J Bone Miner Res. 1996 Oct;11(10):1453-60 [8889845.001]
  • [Cites] J Biol Chem. 1996 Dec 20;271(51):33141-7 [8955163.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Mar 31;95(7):3597-602 [9520411.001]
  • [Cites] Stem Cells. 1998;16(3):229-38 [9617898.001]
  • [Cites] Nature. 1999 Jan 28;397(6717):315-23 [9950424.001]
  • [Cites] J Bone Miner Res. 2004 Dec;19(12):2065-77 [15537451.001]
  • [Cites] Cell. 1997 Apr 18;89(2):309-19 [9108485.001]
  • [Cites] J Biol Chem. 2002 Dec 13;277(50):48808-15 [12374791.001]
  • [Cites] Bone. 2004 May;34(5):827-34 [15121014.001]
  • [Cites] Protein Expr Purif. 2004 Sep;37(1):47-52 [15294280.001]
  • [Cites] J Clin Invest. 2004 Aug;114(4):475-84 [15314684.001]
  • [Cites] J Bone Miner Res. 2004 Nov;19(11):1873-81 [15476588.001]
  • [Cites] J Clin Invest. 1987 Feb;79(2):483-91 [3027126.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Mar;87(5):1663-7 [1689846.001]
  • [Cites] Cancer Genet Cytogenet. 1992 Jan;58(1):2-13 [1728946.001]
  • [Cites] Bone Miner. 1992 Jan;16(1):37-48 [1531620.001]
  • [Cites] Cancer. 1993 Mar 1;71(5):1751-60 [8095436.001]
  • [Cites] J Histochem Cytochem. 1993 Jul;41(7):1075-83 [8515049.001]
  • [Cites] Pathology. 1999 Nov;31(4):373-8 [10643009.001]
  • (PMID = 15972958.001).
  • [ISSN] 0002-9440
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carrier Proteins; 0 / DNA Primers; 0 / Membrane Glycoproteins; 0 / Proteins; 0 / RANK Ligand; 0 / RNA, Messenger; 0 / Receptor Activator of Nuclear Factor-kappa B; 0 / TNFRSF11A protein, human; 0 / TNFSF11 protein, human
  • [Other-IDs] NLM/ PMC1603441
  •  go-up   go-down


71. Arbeitsgemeinschaft Knochentumoren, Becker WT, Dohle J, Bernd L, Braun A, Cserhati M, Enderle A, Hovy L, Matejovsky Z, Szendroi M, Trieb K, Tunn PU: Local recurrence of giant cell tumor of bone after intralesional treatment with and without adjuvant therapy. J Bone Joint Surg Am; 2008 May;90(5):1060-7
Hazardous Substances Data Bank. SODIUM PHENOLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Local recurrence of giant cell tumor of bone after intralesional treatment with and without adjuvant therapy.
  • BACKGROUND: The use of adjuvants after curettage has been well established for the treatment of giant cell tumor of bone.
  • The purpose of this study was to analyze the rates of recurrence following different types of treatment as well as the influence of various factors of tumor presentation on those rates.
  • METHODS: The data regarding benign giant cell tumors of the appendicular skeleton from ten bone tumor centers were evaluated.
  • The recurrence rates associated with the different treatment modalities were analyzed, and hazard ratios for a recurrence were calculated for multiple factors of tumor presentation.
  • The recurrence rate following curettage of a primary tumor without the use of adjuvants (55%) was higher than that following the same treatment of a recurrent tumor (39%) (p = 0.033).
  • CONCLUSIONS: Use of polymethylmethacrylate as an adjuvant significantly reduces the recurrence rate following intralesional treatment of benign giant cell tumors, and it appears to be the therapy of choice for primary as well as recurrent giant cell tumors of bone.
  • The significantly better results following treatment of recurrent tumors without adjuvants compared with the results of the same treatment of primary tumors were probably related to increased surgical thoroughness brought about by the surgeon's awareness of dealing with a riskier tumor.
  • [MeSH-major] Bone Cements / therapeutic use. Bone Neoplasms / therapy. Giant Cell Tumor of Bone / therapy. Neoplasm Recurrence, Local / prevention & control. Polymethyl Methacrylate / therapeutic use

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • Hazardous Substances Data Bank. PHENOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18451399.001).
  • [ISSN] 1535-1386
  • [Journal-full-title] The Journal of bone and joint surgery. American volume
  • [ISO-abbreviation] J Bone Joint Surg Am
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Bone Cements; 339NCG44TV / Phenol; 9011-14-7 / Polymethyl Methacrylate
  •  go-up   go-down


72. Bassiony AA, Abdelrahman M, Abdelhady A, Assal MK: Resection arthrodesis for the management of aggressive giant cell tumor of the distal femur. Indian J Orthop; 2009 Jan;43(1):67-71

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Resection arthrodesis for the management of aggressive giant cell tumor of the distal femur.
  • BACKGROUND: Giant cell tumors (GCTs) of bone are aggressive benign tumors.
  • MATERIALS AND METHODS: Eight patients with mean age of 37.25 years (range 30-45 years) with Campanacci Grade III (Enneking stage III) giant cell tumors at the distal femur were treated with wide resection and arthrodesis using dual free fibular graft and locked intramedullary nail from January 2003 to January 2008.
  • The functional evaluation was done using the standard system of musculoskeletal tumor society with its modification developed by Enneking et al.
  • Graft union was achieved in all cases in a duration mean of 14.5 months (range 12-20 months).One case required secondary bone graft due to delayed union, and one case had superficial wound infection which healed on systemic antibiotics.
  • Resection arthrodesis offers a biological reconstruction alternative to amputation in a special group of patients when extensive resection precludes mobile joint reconstruction.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Bone Joint Surg Br. 1996 Mar;78(2):264-9 [8666639.001]
  • [Cites] Clin Orthop Relat Res. 1993 Jan;(286):241-6 [8425352.001]
  • [Cites] J Bone Joint Surg Am. 1998 May;80(5):636-47 [9611024.001]
  • [Cites] J Bone Joint Surg Am. 1999 Jun;81(6):811-20 [10391546.001]
  • [Cites] Arch Orthop Trauma Surg. 2000;120(3-4):215-8 [10738888.001]
  • [Cites] Clin Orthop Relat Res. 2001 Jul;(388):167-77 [11451116.001]
  • [Cites] J Bone Joint Surg Br. 2004 Jan;86(1):5-12 [14765857.001]
  • [Cites] Ann Acad Med Singapore. 2005 Apr;34(3):235-7 [15902343.001]
  • [Cites] J Surg Oncol. 2005 Oct 1;92(1):46-51 [16180228.001]
  • [Cites] Orthop Clin North Am. 2006 Jan;37(1):35-51 [16311110.001]
  • [Cites] Am J Clin Oncol. 2006 Feb;29(1):96-9 [16462511.001]
  • [Cites] J Bone Joint Surg Br. 2006 Dec;88(12):1642-6 [17159179.001]
  • [Cites] Indian J Orthop. 2007 Apr;41(2):124-8 [21139764.001]
  • [Cites] Indian J Orthop. 2007 Apr;41(2):129-33 [21139765.001]
  • [Cites] J Bone Joint Surg Am. 1990 Dec;72(10):1477-85 [2254355.001]
  • [Cites] J Bone Joint Surg Am. 1990 Apr;72(4):486-94 [2324134.001]
  • [Cites] J Orthop Res. 1989;7(4):463-7 [2738764.001]
  • [Cites] Clin Orthop Relat Res. 1987 Aug;(221):188-201 [3301143.001]
  • [Cites] Arch Orthop Trauma Surg. 1986;105(2):67-72 [3718192.001]
  • [Cites] J Bone Joint Surg Am. 1986 Sep;68(7):1073-9 [3745247.001]
  • [Cites] J Bone Joint Surg Am. 1987 Jan;69(1):106-14 [3805057.001]
  • [Cites] Cancer. 1970 May;25(5):1061-70 [4910256.001]
  • [Cites] J Bone Joint Surg Br. 1994 Mar;76(2):178-86 [8113272.001]
  • [Cites] J Bone Joint Surg Br. 1997 Jan;79(1):36-42 [9020442.001]
  • (PMID = 19753183.001).
  • [ISSN] 0019-5413
  • [Journal-full-title] Indian journal of orthopaedics
  • [ISO-abbreviation] Indian J Orthop
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2739496
  • [Keywords] NOTNLM ; Giant cell tumor / intra medullary nail / resection arthrodesis
  •  go-up   go-down


73. Bispo Júnior RZ, Camargo OP, Ida CM, Baptista AM, Ribeiro MB, Bruno JM, Oliveira CR: Primary malignancy in giant cell tumor: a case report. Sao Paulo Med J; 2009 Sep;127(5):310-3
MedlinePlus Health Information. consumer health - Shoulder Injuries and Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary malignancy in giant cell tumor: a case report.
  • CONTEXT: Primary malignancy in giant cell tumor (PMGCT) is rare.
  • It is defined as a high-grade sarcoma originating in a giant cell tumor (GCT) and seems to behave less aggressively than its secondary counterpart does.
  • CASE REPORT: This report presents the case of a 39-year-old female with pain in her left shoulder for one month.
  • CONCLUSIONS: PMGCT seems to behave less aggressively than secondary malignancy in GCT, and it may simulate its more common benign counterpart clinically and radiographically.
  • [MeSH-major] Bone Neoplasms / pathology. Giant Cell Tumor of Bone / pathology. Neoplasms, Multiple Primary / pathology. Osteosarcoma / pathology. Shoulder Fractures / pathology

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20169281.001).
  • [ISSN] 1806-9460
  • [Journal-full-title] São Paulo medical journal = Revista paulista de medicina
  • [ISO-abbreviation] Sao Paulo Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


74. Karamanakos PN, Jaaskelainen JE, Alafuzoff I, Pirinen E, Vanninen R, Silvennoinen S, Sankilampi U, Immonen A: Malignant giant cell tumor in the posterior fossa of a neonate. J Neurosurg Pediatr; 2010 Mar;5(3):277-82
MedlinePlus Health Information. consumer health - Premature Babies.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant giant cell tumor in the posterior fossa of a neonate.
  • Giant cell tumors (GCTs) of the bone are rare, usually benign but locally aggressive neoplasms that primarily occur in the epiphyses of long bones.
  • Herein, the authors present a case of a highly aggressive primary malignant GCT of the posterior fossa in a 5-week old preterm infant.
  • One month after the gross-total resection of the tumor found in the bone, the infant's condition rapidly deteriorated and she died.
  • Magnetic resonance imaging and postmortem examination revealed a tumor larger than it had been before the operation, with expansion toward the brain.
  • To the best of the authors' knowledge, this is the youngest patient reported with a primary malignant GCT of the skull, and actually the first case in a pediatric patient.
  • In addition, the extremely high growth rate of the tumor in the postoperative period renders this case the most aggressive primary malignant GCT of the cranium described so far.
  • [MeSH-major] Cranial Fossa, Posterior. Giant Cell Tumor of Bone / pathology. Infant, Premature, Diseases / pathology. Skull Base Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20192645.001).
  • [ISSN] 1933-0715
  • [Journal-full-title] Journal of neurosurgery. Pediatrics
  • [ISO-abbreviation] J Neurosurg Pediatr
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


75. Futani H, Okumura Y, Fukuda Y, Fukunaga S, Hasegawa S, Yoshiya S: Giant cell tumor of the sternum: a case report and review of the literature. Anticancer Res; 2008 Nov-Dec;28(6B):4117-20
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant cell tumor of the sternum: a case report and review of the literature.
  • Giant cell tumor (GCT) is a relatively common and locally aggressive benign bone tumor.
  • Extended curettage of the tumor was performed followed by polymethylmethacrylate (PMMA) filing.
  • In conclusion, even though sternal benign tumors are rare, GCT should be considered as one of the differential diagnoses in a patient presenting with a sternal lesion in the 5th or 6th decade of life.
  • [MeSH-major] Bone Neoplasms / pathology. Giant Cell Tumor of Bone / pathology. Sternum / pathology
  • [MeSH-minor] Bone Cements. Female. Humans. Middle Aged. Polymethyl Methacrylate. Reconstructive Surgical Procedures / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19192670.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Bone Cements; 9011-14-7 / Polymethyl Methacrylate
  •  go-up   go-down


76. Schindler OS, Cannon SR, Briggs TW, Blunn GW: Composite ceramic bone graft substitute in the treatment of locally aggressive benign bone tumours. J Orthop Surg (Hong Kong); 2008 Apr;16(1):66-74
Hazardous Substances Data Bank. HYDROXYAPATITE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Composite ceramic bone graft substitute in the treatment of locally aggressive benign bone tumours.
  • PURPOSE: To report the use of a composite ceramic bone graft substitute containing calcium sulphate and hydroxyapatite (HA) in the treatment of large expansive osteolytic benign bone tumours.
  • METHODS: 4 women and 9 men aged 8 to 49 (mean, 22) years with aneurysmal bone cysts (n=6) or giant cell tumours (n=7) in the epi- or meta-physeal areas of the lower limbs underwent curettage, phenolisation, and filling with bone graft substitute containing calcium sulphate and HA.
  • The mean tumour size was 38.5 (range, 18-65) ml.
  • Range of movement, Musculoskeletal Tumor Society Rating Score (MTSRS), and haematological and blood biochemical parameters were measured.
  • RESULTS: Two patients had recurrence at 7 and 9 months, both progressed to grade-III giant cell tumours.
  • CONCLUSION: Composite bioceramic osteoconductive grafts, which combine porous HA with calcium sulphate, provide a framework for human osteogenesis and avoid donor-site morbidity (autologous bone graft harvesting).
  • Tumour recurrence remains a major concern especially in young patients, as revision invariably requires removal of additional bone, potentially compromising joint integrity.
  • [MeSH-major] Bone Cysts, Aneurysmal / surgery. Bone Neoplasms / surgery. Bone Substitutes / therapeutic use. Ceramics / therapeutic use. Durapatite / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Child. Female. Femoral Neoplasms / surgery. Giant Cell Tumor of Bone / surgery. Humans. Male. Middle Aged. Tibia / surgery

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18453663.001).
  • [ISSN] 1022-5536
  • [Journal-full-title] Journal of orthopaedic surgery (Hong Kong)
  • [ISO-abbreviation] J Orthop Surg (Hong Kong)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Bone Substitutes; 91D9GV0Z28 / Durapatite
  •  go-up   go-down


77. Malek F, Krueger P, Hatmi ZN, Malayeri AA, Faezipour H, O'Donnell RJ: Local control of long bone giant cell tumour using curettage, burring and bone grafting without adjuvant therapy. Int Orthop; 2006 Dec;30(6):495-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Local control of long bone giant cell tumour using curettage, burring and bone grafting without adjuvant therapy.
  • Giant cell tumour (GCT) is a benign, but aggressive, primary tumour of the bone.
  • Many surgical techniques have been employed in the treatment of this tumour.
  • In addition to curettage, various adjuvant procedures and packing materials have been advocated in order to control and reconstruct long bone defects secondary to this neoplasm.
  • We report our experience with 40 long bone GCT patients treated with curettage, burring, bone grafting and no adjuvants between 1997 and 2002.
  • The risk of local recurrence in this study is acceptable (within the range that has been historically reported for curettage and bone grafting).
  • [MeSH-major] Bone Neoplasms / surgery. Bone Transplantation / methods. Giant Cell Tumor of Bone / surgery

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Bone Grafts.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Orthop Relat Res. 2002 Apr;(397):259-70 [11953617.001]
  • [Cites] Clin Orthop Relat Res. 2002 Apr;(397):248-58 [11953616.001]
  • [Cites] J Bone Joint Surg Am. 1970 Jun;52(4):619-64 [5479455.001]
  • [Cites] Recent Results Cancer Res. 1976;(54):257-61 [1013500.001]
  • [Cites] J Bone Joint Surg Am. 1980;62(4):652-6 [7380862.001]
  • [Cites] J Bone Joint Surg Am. 1982 Jun;64(5):755-61 [7045129.001]
  • [Cites] Clin Orthop Relat Res. 1986 Mar;(204):9-24 [3456859.001]
  • [Cites] J Bone Joint Surg Am. 1987 Jan;69(1):106-14 [3805057.001]
  • [Cites] Chir Organi Mov. 1990;75(1 Suppl):206 [2249534.001]
  • [Cites] J Bone Joint Surg Am. 1993 Nov;75(11):1648-55 [8245057.001]
  • [Cites] J Bone Joint Surg Am. 1994 Dec;76(12):1827-33 [7989388.001]
  • [Cites] Clin Orthop Relat Res. 1995 Dec;(321):245-50 [7497676.001]
  • [Cites] Bull Hosp Jt Dis. 1998;57(1):6-10 [9553696.001]
  • [Cites] Pathol Int. 1998 Sep;48(9):723-9 [9778111.001]
  • [Cites] J Bone Joint Surg Am. 1999 Jun;81(6):811-20 [10391546.001]
  • [Cites] Bull Hosp Jt Dis. 1999;58(2):98-104 [10509202.001]
  • [Cites] Clin Orthop Relat Res. 2005 Jun;(435):211-8 [15930941.001]
  • [Cites] Clin Orthop Relat Res. 2005 Oct;439:144-50 [16205153.001]
  • [Cites] Clin Orthop Relat Res. 2002 Jul;(400):201-10 [12072763.001]
  • (PMID = 16896875.001).
  • [ISSN] 0341-2695
  • [Journal-full-title] International orthopaedics
  • [ISO-abbreviation] Int Orthop
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Other-IDs] NLM/ PMC3172751
  •  go-up   go-down


78. Fnini S, Labsaili N, Messoudi A, Largab A: [Giant cell tumor of the thumb proximal phalanx: resection-iliac graft and double arthrodesis]. Chir Main; 2008 Feb;27(1):54-7
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Giant cell tumor of the thumb proximal phalanx: resection-iliac graft and double arthrodesis].
  • [Transliterated title] Tumeur à cellules géantes de la phalange proximale du pouce: résection-autogreffe iliaque et arthrodèse bipolaire.
  • Giant cell tumours (GCT) of bone are frequent, with variable behaviour, high risk of recurrence and an often benign histological appearance.
  • [MeSH-major] Bone Neoplasms. Giant Cell Tumor of Bone. Thumb
  • [MeSH-minor] Arthrodesis. Biopsy. Bone Nails. Bone Transplantation. Finger Joint. Follow-Up Studies. Fracture Fixation, Internal / instrumentation. Fractures, Spontaneous / etiology. Fractures, Spontaneous / surgery. Humans. Male. Metacarpophalangeal Joint. Middle Aged. Neoplasm Staging. Patient Satisfaction. Time Factors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18248835.001).
  • [ISSN] 1297-3203
  • [Journal-full-title] Chirurgie de la main
  • [ISO-abbreviation] Chir Main
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


79. Beaufour A, Cazals-Hatem D, Regimbeau JM, Ponsot P, Degott C, Belghiti J, Sauvanet A: [Osteoclastic giant cell tumour of the pancreas]. Gastroenterol Clin Biol; 2005 Feb;29(2):197-200
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Osteoclastic giant cell tumour of the pancreas].
  • [Transliterated title] Tumeur à cellules géantes ostéoclastiques du pancréas.
  • Osteoclast giant cell tumours are bone tumours that occur in adults, and that are considered benign by WHO but locally aggressive.
  • Strictly identical tumours are described in the pancreas, without simultaneous bone localization.
  • We report the case of a 62-year woman with an osteoclast giant cell tumour of the distal pancreas, without any epithelial component, which was diagnosed after pancreatic resection and with no signs of recurrence after a 24-month follow-up.
  • These pancreatic tumours are rare, with a very poor prognosis, an unclear histogenesis; they are often confused with pleomorphic or undifferentiated pancreatic carcinomas including a component of osteoclast giant cell.
  • These osteoclast giant cell tumours of the pancreas usually present as large cystic tumours.
  • [MeSH-major] Giant Cell Tumor of Bone. Pancreatic Neoplasms

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15795672.001).
  • [ISSN] 0399-8320
  • [Journal-full-title] Gastroentérologie clinique et biologique
  • [ISO-abbreviation] Gastroenterol. Clin. Biol.
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


80. Emanuel PO, Shim H, Phelps RG: Poorly differentiated squamous cell carcinoma with osteoclastic giant-cell-like proliferation. J Cutan Pathol; 2007 Dec;34(12):930-3
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Poorly differentiated squamous cell carcinoma with osteoclastic giant-cell-like proliferation.
  • Although osteoclast giant-cell-like proliferations have been reported in a diverse range of human malignancies, to the best of our knowledge, they have never been described in cutaneous squamous cell carcinoma (SCC).
  • Histologically, osteoclastic giant cell tumors within extraosseous malignancy resemble their bony and soft tissue counterparts, with round to spindle-shaped cells admixed with osteoclast-like multinucleate cells.
  • These cells should be distinguished from sarcomatoid differentiation within a carcinoma; they have a benign morphology with a low nuclear to cytoplasmic ratio, minimal pleomorphism/mitoses and negative immunohistochemistry for cytokeratin.
  • The authors report the rare occurrence of osteoclast-like giant cells (OGCs) and accompanying epithelioid histiocytes lacking overtly malignant features in association with a poorly differentiated SCC occurring on sun-damaged skin.
  • The histological differential diagnosis and the origin of the proliferation are discussed in this article.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Giant Cells / pathology. Lip / pathology. Osteoclasts / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Aged, 80 and over. Antigens, CD / metabolism. Antigens, Differentiation, Myelomonocytic / metabolism. Biomarkers, Tumor / analysis. Cell Proliferation. Diagnosis, Differential. Giant Cell Tumor of Bone / pathology. Giant Cell Tumors / pathology. Humans. Immunohistochemistry. Male

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18001416.001).
  • [ISSN] 0303-6987
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Differentiation, Myelomonocytic; 0 / Biomarkers, Tumor; 0 / CD68 antigen, human
  •  go-up   go-down


81. Roeder F, Timke C, Zwicker F, Thieke C, Bischof M, Debus J, Huber PE: Intensity modulated radiotherapy (IMRT) in benign giant cell tumors--a single institution case series and a short review of the literature. Radiat Oncol; 2010;5:18

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intensity modulated radiotherapy (IMRT) in benign giant cell tumors--a single institution case series and a short review of the literature.
  • BACKGROUND: Giant cell tumors are rare neoplasms, representing less than 5% of all bone tumors.
  • The vast majority of giant cell tumors occurs in extremity sites and is treated by surgery alone.
  • Radiation therapy seems to be an option in these patients, despite the lack of a generally accepted dose or fractionation concept.
  • PATIENTS AND METHODS: From 2000 and 2006 a total of five patients with histologically proven benign giant cell tumors have been treated with IMRT in our institution.
  • The tumor was located in the sacral region in four and in the sphenoid sinus in one patient.
  • The remaining four patients have been locally controlled, resulting in a local control rate of 80%.
  • We found no substantial tumor shrinkage after radiotherapy but in two patients morphological signs of extensive tumor necrosis were present on MRI scans.
  • CONCLUSION: IMRT is a feasible option in giant cells tumors not amendable to complete surgical removal.
  • [MeSH-major] Giant Cell Tumor of Bone / radiotherapy. Radiotherapy, Intensity-Modulated

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Bone Joint Surg Br. 1972 May;54(2):216-29 [5034822.001]
  • [Cites] J Bone Joint Surg Am. 1970 Jun;52(4):619-64 [5479455.001]
  • [Cites] Cancer. 1979 Oct;44(4):1393-402 [227563.001]
  • [Cites] J Bone Joint Surg Am. 1982 Jun;64(5):755-61 [7045129.001]
  • [Cites] J Bone Joint Surg Am. 1984 Feb;66(2):269-74 [6693454.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1986 Mar;12(3):329-34 [2420770.001]
  • [Cites] Radiology. 1986 Nov;161(2):537-40 [3763928.001]
  • [Cites] Acta Oncol. 1987 Jan-Feb;26(1):41-3 [3155395.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1989 Nov;17(5):1085-8 [2808042.001]
  • [Cites] Radiother Oncol. 1992 Sep;25(1):56-62 [1410591.001]
  • [Cites] Clin Orthop Relat Res. 1994 May;(302):219-30 [8168305.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Oct 15;33(3):689-94 [7558960.001]
  • [Cites] Radiologe. 1996 Sep;36(9):732-6 [8999450.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Mar 15;43(5):1065-9 [10192357.001]
  • [Cites] Strahlenther Onkol. 1999 May;175(5):197-207 [10356608.001]
  • [Cites] J Bone Joint Surg Am. 1964 Jan;46:63-75 [14104315.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Mar 1;61(3):809-16 [15708260.001]
  • [Cites] Neurosurgery. 2009 Feb;64(2 Suppl):A44-53 [19165073.001]
  • [Cites] Eur J Surg Oncol. 2010 Jan;36(1):84-8 [19682833.001]
  • [Cites] J Bone Joint Surg Am. 1999 Nov;81(11):1566-73 [10565648.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Dec 1;48(5):1371-80 [11121636.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Apr 1;49(5):1239-42 [11286829.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Feb 1;55(2):362-72 [12527049.001]
  • [Cites] Radiother Oncol. 2003 Mar;66(3):313-21 [12742271.001]
  • [Cites] Clin Orthop Relat Res. 2003 Jun;(411):207-16 [12782877.001]
  • [Cites] Strahlenther Onkol. 2003 Aug;179(8):535-41 [14509952.001]
  • [Cites] Clin Orthop Relat Res. 2004 Jun;(423):196-207 [15232449.001]
  • [Cites] Cancer. 1970 May;25(5):1061-70 [4910256.001]
  • [Cites] Radiology. 1977 Oct;125(1):223-6 [408874.001]
  • (PMID = 20187955.001).
  • [ISSN] 1748-717X
  • [Journal-full-title] Radiation oncology (London, England)
  • [ISO-abbreviation] Radiat Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 31
  • [Other-IDs] NLM/ PMC2845594
  •  go-up   go-down


82. Rudic M, Grayeli AB, Cazals-Hatem D, Cyna-Gorse F, Bouccara D, Sterkers O: Temporal bone central giant-cell granuloma presenting as a serous otitis media. Eur Arch Otorhinolaryngol; 2008 May;265(5):587-91
MedlinePlus Health Information. consumer health - Bone Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Temporal bone central giant-cell granuloma presenting as a serous otitis media.
  • Central giant cell granuloma is a benign intraosseous lesion that most commonly occurs in the facial bones.
  • Its location in the temporal bone is extremely rare and only 20 cases have been reported in the literature.
  • CT-scan and MRI revealed a temporal bone tumor involving the mastoid, and surrounding the right temporo-mandibular joint.
  • Tumor was totally removed after a canal-wall-down mastoidectomy and middle ear exclusion.
  • Pathology revealed a central giant cell granuloma.
  • Central giant cell granuloma is a rare temporal bone lesion, with non specific clinical and imaging signs but characteristic pathological features.
  • [MeSH-major] Bone Diseases / diagnosis. Granuloma, Giant Cell / diagnosis. Otitis Media with Effusion / diagnosis. Temporal Bone

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Otolaryngol Head Neck Surg. 1998 Apr;118(4):525-9 [9560106.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1953 Jan;6(1):159-75 [13026160.001]
  • [Cites] Arch Pathol Lab Med. 2003 Sep;127(9):1217-20 [12946217.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006 Mar;101(3):346-54 [16504869.001]
  • [Cites] AJNR Am J Neuroradiol. 2001 May;22(5):873-5 [11337331.001]
  • [Cites] J Neurosurg. 1987 Jun;66(6):924-8 [3572521.001]
  • [Cites] J Clin Neurosci. 2002 Jul;9(4):459-62 [12217681.001]
  • [Cites] Otol Neurotol. 2006 Oct;27(7):999-1002 [16788413.001]
  • [Cites] Mod Pathol. 2001 Dec;14 (12 ):1209-15 [11743042.001]
  • [Cites] AJNR Am J Neuroradiol. 2003 Jun-Jul;24(6):1136-8 [12812940.001]
  • [Cites] J Oral Maxillofac Surg. 2006 Mar;64(3):531-6 [16487820.001]
  • [Cites] Neurosurgery. 1984 Aug;15(2):228-32 [6483139.001]
  • [Cites] Hum Pathol. 1974 Mar;5(2):171-81 [4590573.001]
  • (PMID = 18004584.001).
  • [ISSN] 0937-4477
  • [Journal-full-title] European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  • [ISO-abbreviation] Eur Arch Otorhinolaryngol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


83. Ulu MO, Biceroglu H, Ozlen F, Oz B, Gazioglu N: Giant cell tumor of the frontal bone in an 18-month-old girl: a case report. Cent Eur Neurosurg; 2010 May;71(2):104-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant cell tumor of the frontal bone in an 18-month-old girl: a case report.
  • INTRODUCTION: Giant cell tumors (GCT) are benign, but locally aggressive primary bone neoplasms, that frequently occur in the epiphyses of the long bones.
  • CASE REPORT: The authors report the management of a GCT involving the frontal bone in an 18-month-old girl.
  • CONCLUSION: Although rare, GCTs should be taken into consideration as a differential diagnosis of rapidly enlarging cranial mass lesions in pediatric patients.
  • [MeSH-major] Frontal Bone / pathology. Frontal Bone / surgery. Giant Cell Tumors / pathology. Giant Cell Tumors / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright Georg Thieme Verlag KG Stuttgart . New York.
  • (PMID = 20072990.001).
  • [ISSN] 1868-4912
  • [Journal-full-title] Central European neurosurgery
  • [ISO-abbreviation] Cent Eur Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


84. Hunter CL, Pacione D, Hornyak M, Murali R: Giant-cell tumors of the cervical spine: case report. Neurosurgery; 2006 Nov;59(5):E1142-3; discussion E1143
MedlinePlus Health Information. consumer health - Neck Injuries and Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant-cell tumors of the cervical spine: case report.
  • OBJECTIVE: Giant-cell tumors of bone are rare, benign neoplasms that occur infrequently in the spine above the sacrum, and their presence in the cervical vertebrae is even more exceptional.
  • Although complete en bloc surgical resection is difficult in the cervical spine, treatment with adjuvant radiotherapy has been considered controversial because of a small risk of malignant transformation.
  • The authors report two cases of giant-cell tumors in the cervical vertebrae that were treated successfully with surgical excision and postoperative radiation as well as long-term follow-up.
  • INTERVENTION: In one case, the tumor was treated by anterior resection, then by laminectomy and instrumented fusion, and finally by adjuvant postoperative radiotherapy.
  • However, the tumor recurred, and, after several surgical procedures, external beam radiotherapy was administered.
  • The patients have been followed for 17 and 11 years, respectively, with no evidence of tumor recurrence.
  • CONCLUSION: Radical resection of giant-cell tumors is generally agreed to be the best treatment option.
  • [MeSH-major] Cervical Vertebrae / surgery. Giant Cell Tumor of Bone / diagnosis. Giant Cell Tumor of Bone / surgery. Laminectomy / methods. Spinal Neoplasms / diagnosis. Spinal Neoplasms / surgery. Thoracic Vertebrae / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17143206.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


85. Arpornchayanon O, Leerapun T: Effectiveness of intravenous bisphosphonate in treatment of giant cell tumor: a case report and review of the literature. J Med Assoc Thai; 2008 Oct;91(10):1609-12

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effectiveness of intravenous bisphosphonate in treatment of giant cell tumor: a case report and review of the literature.
  • Giant cell tumor is a benign locally aggressive tumor.
  • The standard treatment is en bloc resection followed by major reconstructive surgery, or extended curettage conjunction with bone grafting or the use of bone cement implantations.
  • Surgical treatment of giant cell tumor at the sacrum is associated with high morbidity, and local recurrence.
  • The authors present a case of giant cell tumor at the sacrum treated with intravenous 4 mg zoledronate every 4 weeks for seven courses followed with curettage and cement implantation.
  • From the present study, the authors demonstrate the effectiveness of zoledronate for treatment of giant cell tumor at the sacrum.
  • [MeSH-major] Bone Density Conservation Agents / therapeutic use. Diphosphonates / therapeutic use. Giant Cell Tumor of Bone / drug therapy. Imidazoles / therapeutic use. Sacrum / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18972907.001).
  • [ISSN] 0125-2208
  • [Journal-full-title] Journal of the Medical Association of Thailand = Chotmaihet thangphaet
  • [ISO-abbreviation] J Med Assoc Thai
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Thailand
  • [Chemical-registry-number] 0 / Bone Density Conservation Agents; 0 / Diphosphonates; 0 / Imidazoles; 6XC1PAD3KF / zoledronic acid
  • [Number-of-references] 15
  •  go-up   go-down


86. Junming M, Cheng Y, Dong C, Jianru X, Xinghai Y, Quan H, Wei Z, Mesong Y, Dapeng F, Wen Y, Bin N, Lianshun J, Huimin L: Giant cell tumor of the cervical spine: a series of 22 cases and outcomes. Spine (Phila Pa 1976); 2008 Feb 1;33(3):280-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant cell tumor of the cervical spine: a series of 22 cases and outcomes.
  • STUDY DESIGN: A consecutive series of 22 giant cell tumor (GCTs) of the cervical spine which underwent surgical treatment was observed from 1990-2003.
  • OBJECTIVE: This study reviews the clinical patterns and follow-up data of (GCT) of bone arising in the cervical spine which underwent surgical treatment.
  • SUMMARY OF BACKGROUND DATA: GCTs of bone are common, aggressive, or low-grade malignant tumors that occur infrequently in the spine above the sacrum, and their presence in the cervical vertebrae is even more exceptional.
  • Though surgical resection of GCT arising in the cervical spine is commonly regarded as a recommended treatment method, it is still a challenge to achieve satisfactory results, especially for the late or recurrent cases, and there are few large series of cases reported with long-term follow-up of this tumor that are found in special segments in the literature.
  • For reconstructing the stability of the cervical spine, we used autologous ilium for pure bone graft, or titanium plate and titanium mesh for anterior instrumented fusion or anterior and posterior combined instrumented fusion.
  • RESULTS: One patient with C1-C2 GCT (vertebral body and posterior element involvement) who received subtotal resection of the tumor showed aggravation of neurologic deficit and died shortly after the surgery.
  • The rate of fusion for the bone graft is 100%.
  • As a kind of benign but local aggressive or low potential malignancy tumor, we should take an aggressive attitude to excise the tumor as much as possible while reserving the neural function as a precondition.
  • [MeSH-major] Bone Neoplasms / surgery. Cervical Vertebrae / surgery. Giant Cell Tumor of Bone / surgery. Spinal Neoplasms / surgery


87. Matsumoto Y, Okada Y, Fukushi J, Kamura S, Fujiwara T, Iida K, Koga M, Matsuda S, Harimaya K, Sakamoto A, Iwamoto Y: Role of the VEGF-Flt-1-FAK pathway in the pathogenesis of osteoclastic bone destruction of giant cell tumors of bone. J Orthop Surg Res; 2010;5:85
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of the VEGF-Flt-1-FAK pathway in the pathogenesis of osteoclastic bone destruction of giant cell tumors of bone.
  • BACKGROUND: Giant cell tumors (GCTs) of bone are primary benign bone tumors that are characterized by a high number of osteoclast-like multinuclear giant cells (MNCs).
  • Recent studies suggest that the spindle-shaped stromal cells in GCTs are tumor cells, while monocyte-like cells and MNCs are reactive osteoclast precursor cells (OPCs) and osteoclasts (OCs), respectively.
  • In this study, we investigated the pathogenesis of osteoclastic bone destruction in GCTs by focusing on the role of the vascular endothelial growth factor (VEGF)-Flt-1 (type-1 VEGF receptor)-focal adhesion kinase (FAK) pathway.
  • METHODS: The motility of OPCs cells was assessed by a chemotaxis assay and the growth of OPCs was examined using a cell proliferation assay.
  • CONCLUSIONS: Our results suggest that the VEGF-Flt-1-FAK pathway is involved in the pathogenesis of bone destruction of GCTs.


88. Skubitz KM, Manivel JC: Giant cell tumor of the uterus: case report and response to chemotherapy. BMC Cancer; 2007;7:46
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant cell tumor of the uterus: case report and response to chemotherapy.
  • BACKGROUND: Giant cell tumor (GCT) is usually a benign but locally aggressive primary bone neoplasm in which monocytic macrophage/osteoclast precursor cells and multinucleated osteoclast-like giant cells infiltrate the tumor.
  • The etiology of GCT is unknown, however the tumor cells of GCT have been reported to produce chemoattractants that can attract osteoclasts and osteoclast precursors.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Giant Cell Tumors / drug therapy. Uterine Neoplasms / drug therapy
  • [MeSH-minor] Angiogenesis Inhibitors / administration & dosage. Antibiotics, Antineoplastic / administration & dosage. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Humanized. Antineoplastic Agents, Alkylating / administration & dosage. Bevacizumab. Combined Modality Therapy. Doxorubicin / administration & dosage. Female. Humans. Hysterectomy. Ifosfamide / administration & dosage. Lung Neoplasms / diagnosis. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Middle Aged. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AJR Am J Roentgenol. 1992 Feb;158(2):331-4 [1729794.001]
  • [Cites] APMIS Suppl. 1991;23:113-8 [1883635.001]
  • [Cites] Cancer. 1993 Nov 15;72(10):2963-9 [8221562.001]
  • [Cites] Clin Orthop Relat Res. 1994 May;(302):219-30 [8168305.001]
  • [Cites] Am J Clin Oncol. 1995 Apr;18(2):144-8 [7900706.001]
  • [Cites] Pathol Int. 1996 Sep;46(9):656-60 [8905874.001]
  • [Cites] Clin Orthop Relat Res. 1997 Feb;(335):253-61 [9020226.001]
  • [Cites] J Clin Oncol. 1997 Jun;15(6):2378-84 [9196153.001]
  • [Cites] Cell. 1998 Apr 17;93(2):165-76 [9568710.001]
  • [Cites] Surg Neurol. 1998 May;49(5):547-52 [9586934.001]
  • [Cites] J Cell Biochem. 1998 Jul 1;70(1):121-9 [9632113.001]
  • [Cites] J Clin Oncol. 1998 Jul;16(7):2445-51 [9667262.001]
  • [Cites] Int Orthop. 1998;22(3):200-4 [9728318.001]
  • [Cites] Pediatrics. 1999 Jun;103(6 Pt 1):1282-3 [10353942.001]
  • [Cites] Rev Chir Orthop Reparatrice Appar Mot. 1999 Jun;85(3):293-6 [10422135.001]
  • [Cites] J Exp Med. 1999 Jul 19;190(2):293-8 [10432291.001]
  • [Cites] J Cancer Res Clin Oncol. 1999 Oct;125(10):577-81 [10473871.001]
  • [Cites] Cancer. 2005 Jul 15;104(2):361-6 [15948172.001]
  • [Cites] J Clin Oncol. 2001 Aug 1;19(15):3483-9 [11481354.001]
  • [Cites] Am J Clin Pathol. 2002 Feb;117(2):210-6 [11863217.001]
  • [Cites] Cancer. 2002 Jun 15;94(12):3225-9 [12115355.001]
  • [Cites] Clin Orthop Relat Res. 2002 Aug;(401):202-8 [12151897.001]
  • [Cites] J Oral Maxillofac Surg. 2002 Oct;60(10):1103-11; discussion 1111-3 [12378481.001]
  • [Cites] Cancer Invest. 2003 Apr;21(2):167-76 [12743981.001]
  • [Cites] Life Sci. 2003 Aug 1;73(11):1427-36 [12850503.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Sep 1;57(1):158-65 [12909228.001]
  • [Cites] Br J Surg. 2004 Feb;91(2):242-7 [14760675.001]
  • [Cites] Orthopade. 2004 Mar;33(3):344-8 [15007559.001]
  • [Cites] Skeletal Radiol. 2004 May;33(5):295-9 [14997349.001]
  • [Cites] J Lab Clin Med. 2004 Aug;144(2):78-91 [15322502.001]
  • [Cites] Clin Orthop Relat Res. 2004 Sep;(426):32-8 [15346048.001]
  • [Cites] Clin Orthop Relat Res. 2004 Sep;(426):103-9 [15346059.001]
  • [Cites] Clin Cancer Res. 2004 Sep 1;10(17):5732-40 [15355900.001]
  • [Cites] Calcif Tissue Int. 2004 Jul;75(1):71-7 [15037971.001]
  • [Cites] J Lab Clin Med. 2004 Oct;144(4):193-200 [15514587.001]
  • [Cites] Cancer. 1968 Aug;22(2):333-44 [5660199.001]
  • [Cites] Endocrinology. 1972 Oct;91(4):916-20 [5051344.001]
  • [Cites] Cancer. 1973 Mar;31(3):621-5 [4693590.001]
  • [Cites] Cancer. 1975 Aug;36(2):495-504 [50874.001]
  • [Cites] Science. 1975 Nov 21;190(4216):784-5 [1105786.001]
  • [Cites] Virchows Arch A Pathol Anat Histol. 1976 Sep 21;371(3):199-217 [184582.001]
  • [Cites] Acta Pathol Microbiol Scand A. 1981 Mar;89(2):179-84 [7270164.001]
  • [Cites] Cancer. 1981 Nov 1;48(9):2022-8 [7296510.001]
  • [Cites] Arkh Patol. 1983;45(2):78-82 [6847417.001]
  • [Cites] J Bone Joint Surg Am. 1985 Jul;67(6):890-900 [4019539.001]
  • [Cites] Nature. 1999 Nov 18;402(6759):304-9 [10580503.001]
  • [Cites] Am J Pathol. 2000 Mar;156(3):761-7 [10702390.001]
  • [Cites] J Bone Miner Res. 2000 Apr;15(4):640-9 [10780856.001]
  • [Cites] Hum Pathol. 2000 Jul;31(7):804-12 [10923916.001]
  • [Cites] Eur J Cancer. 2001 May;37(7):870-7 [11313175.001]
  • [Cites] J Pathol. 1985 Nov;147(3):153-8 [4067733.001]
  • [Cites] Gynecol Oncol. 1986 Mar;23(3):381-6 [3957125.001]
  • [Cites] J Clin Invest. 1987 Feb;79(2):483-91 [3027126.001]
  • [Cites] Clin Orthop Relat Res. 1988 Dec;(237):275-85 [3056645.001]
  • [Cites] Clin Orthop Relat Res. 1989 Jun;(243):208-15 [2656024.001]
  • [Cites] Cancer. 1990 Apr 15;65(8):1838-42 [2317762.001]
  • [Cites] J Cancer Res Clin Oncol. 1993;119(5):301-3 [8440744.001]
  • (PMID = 17359524.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibiotics, Antineoplastic; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents, Alkylating; 2S9ZZM9Q9V / Bevacizumab; 80168379AG / Doxorubicin; UM20QQM95Y / Ifosfamide
  • [Number-of-references] 57
  • [Other-IDs] NLM/ PMC1832205
  •  go-up   go-down


89. Lietman SA, Prescott NL, Hicks DG, Westra WH, Levine MA: SH3BP2 is rarely mutated in exon 9 in giant cell lesions outside cherubism. Clin Orthop Relat Res; 2007 Jun;459:22-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] SH3BP2 is rarely mutated in exon 9 in giant cell lesions outside cherubism.
  • Giant cell tumor of bone and giant cell reparative granuloma are benign lesions with prominent giant (multinucleated) cells, and an understanding of the molecular biology and genetics of these lesions will likely aid in more effective treatment.
  • Cherubism is a benign lesion of the maxilla and mandible histologically similar to giant cell tumor of bone and giant cell reparative granuloma.
  • We therefore hypothesized SH3BP2 and its putative downstream effector nuclear factor of activated T cells c1 isoform (NFATc1) are highly expressed in sporadic nonsyndromic giant cell lesions and associated with somatic SH3BP2 mutations.
  • We analyzed giant cell lesions for SH3BP2 and NFATc1 expression by RNA blot and/or immunohistochemistry and for exon 9 SH3BP2 mutations.
  • We found the SH3BP2 transcripts and protein were abundantly expressed in giant cell tumors of bone, as well as NFATc1 protein.
  • Sequencing of exon 9 of SH3BP2 was normal in all sporadic nonsyndromic giant cell lesions.
  • Although many multinucleated giant cell lesions of bone share histologic features, the primary genetic defect in cherubism and these other giant cell lesions appears different.
  • [MeSH-major] Adaptor Proteins, Signal Transducing / metabolism. Bone Neoplasms / metabolism. Cherubism / metabolism. Giant Cell Tumor of Bone / metabolism. NFATC Transcription Factors / metabolism

  • Genetic Alliance. consumer health - Cherubism.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17545756.001).
  • [ISSN] 0009-921X
  • [Journal-full-title] Clinical orthopaedics and related research
  • [ISO-abbreviation] Clin. Orthop. Relat. Res.
  • [Language] eng
  • [Grant] United States / NIAMS NIH HHS / AR / K08 AR477661
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / NFATC Transcription Factors; 0 / NFATC1 protein, human; 0 / RNA, Messenger; 0 / SH3BP2 protein, human
  •  go-up   go-down


90. Kapoor SK, Tiwari A: Resection arthrodesis for giant cell tumors around the knee. Indian J Orthop; 2007 Apr;41(2):124-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Resection arthrodesis for giant cell tumors around the knee.
  • BACKGROUND: Giant cell tumors (GCTs) of bone are aggressive benign tumors.
  • MATERIALS AND METHODS: Thirty-six patients of mean age 33.1 years with Campanacci Grade III giant cell tumors around the knee (20 distal femoral and 16 proximal tibial) were treated with wide resection and arthrodesis from January 1996 through January 2006.
  • Arthrodesis was performed using plating with free fibular graft (n = 18), IM nail with free fibular graft (n = 8) and IM nail combined with ring fixator using bone transport (n = 10).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21139764.001).
  • [ISSN] 0019-5413
  • [Journal-full-title] Indian journal of orthopaedics
  • [ISO-abbreviation] Indian J Orthop
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2989135
  • [Keywords] NOTNLM ; Giant cell tumor; knee / resection arthrodesis
  •  go-up   go-down


91. James SL, Davies AM: Giant-cell tumours of bone of the hand and wrist: a review of imaging findings and differential diagnoses. Eur Radiol; 2005 Sep;15(9):1855-66
MedlinePlus Health Information. consumer health - Diagnostic Imaging.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant-cell tumours of bone of the hand and wrist: a review of imaging findings and differential diagnoses.
  • Giant-cell tumour of bone (GCTOB) is a benign, locally aggressive, primary bone tumour.
  • GCTOB involving the bones of the hand most commonly occurs in a central location, which differs from the usual eccentric location seen in GCTOB at other sites.
  • The role of bone scintigraphy, computed tomography and magnetic resonance imaging is discussed.
  • [MeSH-major] Bone Neoplasms / diagnosis. Carpal Bones / pathology. Diagnostic Imaging. Giant Cell Tumor of Bone / diagnosis. Hand Bones / pathology
  • [MeSH-minor] Diagnosis, Differential. Humans. Magnetic Resonance Imaging. Radiopharmaceuticals. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Bone Joint Surg Am. 1985 Jul;67(6):890-900 [4019539.001]
  • [Cites] J Bone Joint Surg Am. 1983 Oct;65(8):1179-80 [6355113.001]
  • [Cites] Orthopedics. 1995 May;18(5):482-4 [7610097.001]
  • [Cites] Clin Radiol. 1998 Jul;53(7):481-9 [9714386.001]
  • [Cites] Skeletal Radiol. 1987;16(8):635-43 [3423832.001]
  • [Cites] J Bone Joint Surg Am. 1970 Jun;52(4):619-64 [5479455.001]
  • [Cites] AJR Am J Roentgenol. 2004 Nov;183(5):1453-63 [15505320.001]
  • [Cites] Orthopedics. 2001 Nov;24(11):1085-6 [11727811.001]
  • [Cites] J Hand Surg Am. 1977 Jul;2(4):269-70 [893983.001]
  • [Cites] AJR Am J Roentgenol. 2003 Dec;181(6):1583-9 [14627578.001]
  • [Cites] Radiology. 1992 Jul;184(1):233-7 [1609086.001]
  • [Cites] Hand. 1982 Feb;14 (1):93-6 [6277748.001]
  • [Cites] J Bone Joint Surg Am. 1987 Jan;69(1):106-14 [3805057.001]
  • [Cites] Clin Orthop Relat Res. 1996 Feb;(323):60-4 [8625607.001]
  • [Cites] Clin Orthop Relat Res. 1989 Jun;(243):208-15 [2656024.001]
  • [Cites] Eur Radiol. 2003 Aug;13(8):1820-35 [12700923.001]
  • [Cites] J Bone Joint Surg Br. 1998 Jan;80(1):43-7 [9460951.001]
  • [Cites] J Hand Surg Am. 1994 Nov;19(6):1003-5 [7876470.001]
  • [Cites] J Bone Joint Surg Am. 1986 Sep;68(7):1073-9 [3745247.001]
  • [Cites] J Hand Surg Am. 1980 Jan;5(1):39-50 [7365216.001]
  • [Cites] J Hand Surg Am. 2004 Mar;29(2):188-93 [15043887.001]
  • [Cites] Clin Radiol. 2000 Sep;55(9):717-8 [10988053.001]
  • [Cites] J Hand Surg Am. 1995 May;20(3):432-40 [7642922.001]
  • [Cites] Clin Orthop Relat Res. 2001 Feb;(383):221-8 [11210959.001]
  • [Cites] Radiologe. 2001 Jul;41(7):577-82 [11490778.001]
  • [Cites] Ann R Coll Surg Engl. 2004 Jan;86(1):18-24 [15005940.001]
  • [Cites] J Bone Joint Surg Am. 1977 Dec;59(8):1052-60 [591535.001]
  • [Cites] J Bone Joint Surg Br. 1995 Mar;77(2):189-93 [7706330.001]
  • [Cites] Clin Orthop Relat Res. 1996 Jan;(322):245-52 [8542701.001]
  • [Cites] Orthopedics. 1997 Jan;20(1):67-9 [9122055.001]
  • [Cites] J Bone Joint Surg Am. 1980;62(4):652-6 [7380862.001]
  • [Cites] J Hand Surg Am. 1977 Jul;2(4):299-308 [330615.001]
  • [Cites] Radiology. 1998 Sep;208(3):821-8 [9722866.001]
  • [Cites] Z Orthop Ihre Grenzgeb. 1981 Aug;119(4):427-9 [7293356.001]
  • [Cites] Chir Organi Mov. 1990;75(1 Suppl):204-5 [2249533.001]
  • [Cites] Clin Orthop Relat Res. 1992 Jan;(274):270-4 [1729012.001]
  • [Cites] Cancer. 1979 Oct;44(4):1393-402 [227563.001]
  • [Cites] Ann Plast Surg. 1996 Jul;37(1):55-9 [8826593.001]
  • [Cites] J Bone Joint Surg Am. 1994 Dec;76(12):1827-33 [7989388.001]
  • [Cites] Orthopade. 2000 Jul;29(7):677-83 [10986714.001]
  • [Cites] J Bone Joint Surg Am. 1983 Apr;65(4):486-90 [6833323.001]
  • [Cites] Cancer. 1970 May;25(5):1061-70 [4910256.001]
  • [Cites] Cancer. 2000 May 1;88(9):2022-32 [10813712.001]
  • [Cites] J Bone Joint Surg Am. 1999 Jun;81(6):811-20 [10391546.001]
  • [Cites] J Hand Surg Am. 1987 Jan;12 (1):70-7 [3805646.001]
  • [Cites] J Hand Surg Am. 1984 May;9(3):391-8 [6725899.001]
  • [Cites] J Hand Surg Am. 1997 Jan;22(1):91-8 [9018620.001]
  • [Cites] Skeletal Radiol. 1990;19(2):85-90 [2321049.001]
  • [Cites] Clin Orthop Relat Res. 1998 Jul;(352):187-93 [9678047.001]
  • [Cites] J Bone Joint Surg Am. 1984 Feb;66(2):269-74 [6693454.001]
  • [Cites] Eur Radiol. 2004 Oct;14 (10 ):1761-9 [15221263.001]
  • [Cites] Radiology. 1983 Oct;149(1):65-8 [6611953.001]
  • [Cites] AJR Am J Roentgenol. 1996 Jan;166(1):145-8 [8571864.001]
  • [Cites] J Bone Joint Surg Am. 1986 Jun;68(5):687-94 [3722225.001]
  • [Cites] Scand J Plast Reconstr Surg Hand Surg. 2000 Dec;34(4):397-9 [11195881.001]
  • [Cites] J Surg Oncol. 1983 Oct;24(2):99-102 [6632902.001]
  • [Cites] J Hand Surg Am. 1984 Mar;9(2):272-4 [6715840.001]
  • [Cites] Skeletal Radiol. 1984;12 (2):79-89 [6484605.001]
  • [Cites] Semin Diagn Pathol. 1984 Aug;1(3):173-84 [6599927.001]
  • [Cites] Clin Orthop Relat Res. 1986 Mar;(204):45-58 [3514036.001]
  • [Cites] J Bone Joint Surg Br. 1997 Jan;79(1):26-30 [9020440.001]
  • [Cites] J Hand Surg Am. 1982 Nov;7(6):593-600 [7175130.001]
  • [Cites] Med J Malaysia. 2000 Sep;55 Suppl C:105-6 [11200036.001]
  • [Cites] J Bone Joint Surg Am. 1982 Jun;64(5):755-61 [7045129.001]
  • [Cites] J Hand Surg Br. 1996 Oct;21(5):683-7 [9230964.001]
  • [Cites] Clin Orthop Relat Res. 2003 Nov;(416):278-84 [14646771.001]
  • [Cites] Clin Orthop Relat Res. 1999 Feb;(359):176-88 [10078141.001]
  • [Cites] Clin Orthop Relat Res. 1994 May;(302):219-30 [8168305.001]
  • [Cites] Skeletal Radiol. 1994 Apr;23(3):187-90 [8016669.001]
  • [Cites] Radiographics. 2001 Sep-Oct;21(5):1283-309 [11553835.001]
  • [Cites] Hand Clin. 2004 Aug;20(3):269-81, vi [15275686.001]
  • [Cites] J Bone Joint Surg Am. 1981 Jul;63(6):877-84 [7240328.001]
  • [Cites] Radiographics. 1990 Jan;10 (1):83-102 [2296699.001]
  • [Cites] Eur Radiol. 1998;8(5):791-9 [9601967.001]
  • [Cites] Skeletal Radiol. 1984;11(2):85-95 [6322349.001]
  • [Cites] Chir Organi Mov. 1990 Jan-Mar;75(1):77-80 [2369858.001]
  • [Cites] AJR Am J Roentgenol. 1992 Feb;158(2):331-4 [1729794.001]
  • [Cites] J Bone Joint Surg Br. 2004 Jan;86(1):5-12 [14765857.001]
  • [Cites] J Bone Joint Surg Am. 1986 Feb;68(2):235-42 [3511063.001]
  • [Cites] J Bone Joint Surg Am. 1996 Jan;78(1):106-10 [8550667.001]
  • [Cites] J Hand Surg Br. 1998 Apr;23(2):279-80 [9607683.001]
  • [Cites] Skeletal Radiol. 1992;21(5):335-8 [1502590.001]
  • (PMID = 15868123.001).
  • [ISSN] 0938-7994
  • [Journal-full-title] European radiology
  • [ISO-abbreviation] Eur Radiol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Radiopharmaceuticals
  • [Number-of-references] 89
  •  go-up   go-down


92. Jeys LM, Suneja R, Chami G, Grimer RJ, Carter SR, Tillman RM: Impending fractures in giant cell tumours of the distal femur: incidence and outcome. Int Orthop; 2006 Apr;30(2):135-8
MedlinePlus Health Information. consumer health - Leg Injuries and Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impending fractures in giant cell tumours of the distal femur: incidence and outcome.
  • Giant cell tumours are rare bone tumours that are characteristically benign but locally aggressive, most frequently occurring in the distal femur with pathological fractures being common.
  • This paper investigates relationships between tumour size and cortical breach on initial X-rays and subsequent treatment.
  • The X-rays of 54 patients with distal femoral giant cell tumours were reviewed.
  • The volumes of the tumour, distal femur and a ratio between the two parameters were estimated.
  • The presence of a cortical breach, discrete fracture and Campanacci grade was recorded.
  • There was a significant difference in the ratio of tumour volume to distal femoral volume between the discrete fracture group and the cortical breach group.
  • [MeSH-major] Femoral Fractures / epidemiology. Femoral Fractures / physiopathology. Femoral Neoplasms / physiopathology. Giant Cell Tumor of Bone / physiopathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Orthop Relat Res. 2002 Apr;(397):248-58 [11953616.001]
  • [Cites] J Bone Joint Surg Br. 2004 Jan;86(1):5-12 [14765857.001]
  • [Cites] J Bone Joint Surg Am. 1970 Jun;52(4):619-64 [5479455.001]
  • [Cites] J Bone Joint Surg Am. 1975 Mar;57(2):167-73 [1112843.001]
  • [Cites] J Bone Joint Surg Am. 1976 Dec;58(8):1047-55 [1002744.001]
  • [Cites] J Bone Joint Surg Am. 1982 Jun;64(5):755-61 [7045129.001]
  • [Cites] J Bone Joint Surg Br. 1995 Mar;77(2):189-93 [7706330.001]
  • [Cites] Clin Orthop Relat Res. 1986 Feb;(203):282-8 [3955991.001]
  • [Cites] Arch Orthop Trauma Surg. 1986;105(2):67-72 [3718192.001]
  • [Cites] J Bone Joint Surg Am. 1987 Jan;69(1):106-14 [3805057.001]
  • [Cites] Clin Orthop Relat Res. 1989 Dec;(249):256-64 [2684463.001]
  • [Cites] Chir Organi Mov. 1990;75(1 Suppl):203 [2249532.001]
  • [Cites] Chir Organi Mov. 1990;75(1 Suppl):241-3 [2249540.001]
  • [Cites] J Bone Joint Surg Am. 1986 Feb;68(2):235-42 [3511063.001]
  • (PMID = 16474936.001).
  • [ISSN] 0341-2695
  • [Journal-full-title] International orthopaedics
  • [ISO-abbreviation] Int Orthop
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Other-IDs] NLM/ PMC2532068
  •  go-up   go-down


93. Kijima Y, Umekita Y, Yoshinaka H, Taguchi S, Owaki T, Funasako Y, Sakamoto A, Yoshida H, Aikou T: Stromal sarcoma with features of giant cell malignant fibrous histiocytoma. Breast Cancer; 2007;14(2):239-44
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stromal sarcoma with features of giant cell malignant fibrous histiocytoma.
  • We report a case of primary giant cell malignant fibrous histiocytoma (GCMFH) of the breast.
  • Mammography and ultrasonography revealed a well-circumscribed and lobulated mass in the upper outer quadrant of the right breast, indicative of a benign breast tumor or mucinous carcinoma.
  • Magnetic resonance imaging revealed a restricted breast tumor without intraductal spread.
  • Computed tomography and bone scintigraphy found no sites of distant metastases.
  • Fine needle aspiration biopsy showed several clusters of atypical cells associated with numerous multinucleated giant cells.
  • No metastases were identified in any of the 15 left axillary lymph nodes resected and surgical margins were free from tumor cells.
  • The tumor was negative for both estrogen and progesterone receptor.
  • [MeSH-major] Breast Neoplasms / pathology. Giant Cell Tumors / pathology. Histiocytoma, Malignant Fibrous / pathology

  • Genetic Alliance. consumer health - Malignant fibrous histiocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17485912.001).
  • [ISSN] 1340-6868
  • [Journal-full-title] Breast cancer (Tokyo, Japan)
  • [ISO-abbreviation] Breast Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 28
  •  go-up   go-down


94. Boneschi V, Parafioriti A, Armiraglio E, Gaiani F, Brambilla L: Primary giant cell tumor of soft tissue of the groin - a case of 46 years duration. J Cutan Pathol; 2009 Oct;36 Suppl 1:20-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary giant cell tumor of soft tissue of the groin - a case of 46 years duration.
  • BACKGROUND: Soft tissue giant cell tumor (GCT-ST) of low malignant potential is an uncommon neoplasm, considered the soft tissue counterpart of giant cell tumor of bone.
  • Histologically, this tumor is characterized by a mixture of uniformly scattered osteoclast-like multinucleated giant cells intimately admixed with short fascicles of spindled cells.
  • Complete excision with negative surgical margins is associated with a benign clinical course in most cases.
  • RESULTS: Histologically, the tumor was characterized by a multinodular growth pattern with osteoclast-like multinucleated giant cells admixed with spindle cells partially arranged in a storiform pattern, fibrosis and foci of haemorrhage and mature bone.
  • Immunohistochemistry revealed CD68 reactivity of the multinucleated giant cells.
  • CONCLUSION: GCT-ST is a rare neoplasm characterized by benign clinical course if excised adequately, as shown by our case of exceptionally long duration.
  • Emphasis is placed on the importance of differential diagnosis with other giant cell-rich soft tissue neoplasms because clinical behaviour, prognosis and treatment significantly differ.
  • [MeSH-major] Giant Cell Tumors / pathology. Groin / pathology. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Age of Onset. Aged. Antigens, CD / biosynthesis. Antigens, Differentiation, Myelomonocytic / biosynthesis. Biopsy. Diagnostic Errors. Humans. Immunohistochemistry. Male. Sarcoma, Kaposi / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19222697.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Differentiation, Myelomonocytic; 0 / CD68 antigen, human
  •  go-up   go-down


95. Fernández-Aguilar S, Noël JC: [Malignant phyllodes tumor of the breast with osteoclast-like giant cells: a case report]. Ann Pathol; 2007 Feb;27(1):31-4
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant phyllodes tumor of the breast with osteoclast-like giant cells: a case report].
  • [Transliterated title] Tumeur phyllode maligne du sein avec cellules géantes de type ostéoclastique: à propos d'un cas.
  • Breast tumors, particularly of stromal origin, containing multinucleated osteoclast-like giant cells (OLGC) are rarely reported in the literature.
  • We report here the first case of a malignant phyllodes tumor associated with OLGC occurring in a 43 year-old African woman who presented with a painful palpable mass of the outer upper quadrant of the right breast.
  • After surgical excision, histological examination showed a malignant phyllodes tumor in which the stromal component displayed evident sarcomatous changes and was densely populated with benign multinucleated OLGC.
  • This lesion ressembles giant cell tumor of bone.
  • [MeSH-major] Breast Neoplasms / pathology. Giant Cells / pathology. Osteoclasts / pathology. Phyllodes Tumor / pathology

  • Genetic Alliance. consumer health - Phyllodes Tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17568357.001).
  • [ISSN] 0242-6498
  • [Journal-full-title] Annales de pathologie
  • [ISO-abbreviation] Ann Pathol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


96. Roberts DS, Faquin WC, Deschler DG: Giant cell tumors of the temporal bone and infratemporal fossa: a case report and review of the literature. Laryngoscope; 2010;120 Suppl 4:S180
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant cell tumors of the temporal bone and infratemporal fossa: a case report and review of the literature.
  • OBJECTIVES: To report a giant cell tumor (GCT) of temporal bone and infratemporal fossa and to review the literature pertinent to the care of such patients.
  • METHODS: A review of the literature was conducted using Pubmed and the key words temporal bone, GCT, infratemporal fossa, and recurrent GCT.
  • RESULTS: Six case reports over 23 years illustrate that these benign locally destructive lesions may originate in the temporal bone with extension into the infratemporal fossa.
  • We present a 30 year-old male who developed a temporal bone GCT with infratemporal fossa extension 12 years after undergoing successful surgical treatment of a GCT of the femur.
  • CONCLUSION: Due to the risk for recurrence, complete resection of GCTs of the temporal bone and infratemporal fossa is advocated.
  • [MeSH-major] Bone Neoplasms / surgery. Giant Cell Tumor of Bone / surgery. Temporal Bone / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21225778.001).
  • [ISSN] 1531-4995
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


97. Moskovszky L, Szuhai K, Krenács T, Hogendoorn PC, Szendroi M, Benassi MS, Kopper L, Füle T, Sápi Z: Genomic instability in giant cell tumor of bone. A study of 52 cases using DNA ploidy, relocalization FISH, and array-CGH analysis. Genes Chromosomes Cancer; 2009 Jun;48(6):468-79
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genomic instability in giant cell tumor of bone. A study of 52 cases using DNA ploidy, relocalization FISH, and array-CGH analysis.
  • Genetic instability in relation to clinical behavior was studied in 52 cases of giant cell tumor of bone (GCTB).
  • Ploidy was determined in the mononuclear cell population by using native cell smears and image cytometry.
  • Genome-wide alterations were tested using array comparative genomic hybridization (array-CGH) on magnetically separated CD68-negative tumor cells.
  • Random individual-cell aneusomy was significantly (P < 0.001) more frequent in the recurrent groups (36.01 +/- 11.94%) than in the benign nonrecurrent cases (10.65 +/- 3.66%).
  • [MeSH-major] Bone Neoplasms / genetics. Genomic Instability. Giant Cell Tumor of Bone / genetics. Ploidies
  • [MeSH-minor] Adolescent. Adult. Aged. Antigens, CD / genetics. Antigens, CD / metabolism. Antigens, Differentiation, Myelomonocytic / genetics. Antigens, Differentiation, Myelomonocytic / metabolism. Centromere / metabolism. Chi-Square Distribution. Chromosomes, Human, Pair 11. Comparative Genomic Hybridization. Female. Humans. In Situ Hybridization, Fluorescence. Male. Middle Aged. Neoplasm Proteins / genetics. Neoplasm Proteins / metabolism. Oligonucleotide Array Sequence Analysis. Proto-Oncogene Proteins c-bcl-2 / genetics. Proto-Oncogene Proteins c-bcl-2 / metabolism. Telomere / genetics. Telomere / metabolism. Tumor Suppressor Protein p53 / genetics. Tumor Suppressor Protein p53 / metabolism. beta Catenin / genetics. beta Catenin / metabolism

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19242928.001).
  • [ISSN] 1098-2264
  • [Journal-full-title] Genes, chromosomes & cancer
  • [ISO-abbreviation] Genes Chromosomes Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Differentiation, Myelomonocytic; 0 / CD68 antigen, human; 0 / CTNNB1 protein, human; 0 / Neoplasm Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Tumor Suppressor Protein p53; 0 / beta Catenin
  •  go-up   go-down


98. Riddle ND, Yamauchi H, Caracciolo JT, Cheong D, Khakpour N, Bui MM: Giant cell tumor of the anterior rib masquerading as a breast mass: a case report and review of current literature. Cases J; 2010;3:51
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant cell tumor of the anterior rib masquerading as a breast mass: a case report and review of current literature.
  • INTRODUCTION: Giant cell tumor (GCT) is an aggressive, but usually benign bone neoplasm most commonly arising in the metaphysis/epiphyses of long bones.
  • While they are categorized as benign tumors, they can be locally aggressive and clinically have metastatic potential.
  • The most common locations of this tumor include the distal femur, proximal tibia, and distal radius.
  • Histological examination of the biopsy specimen showed bland multi-nucleated giant cells and mononuclear cells whose nuclei were morphologically similar.
  • CONCLUSION: The histological features of bland mononuclear and multinucleated giant cells along with the lack of any additional mesenchymal elements led to the diagnosis of giant cell tumor.
  • Resection of tumor was performed.
  • This case is important as it shows where the physician must keep this diagnosis in mind whenever a deeply located breast mast is present.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Skeletal Radiol. 1992;21(7):482-8 [1439904.001]
  • [Cites] Respir Med. 1991 Sep;85(5):435-6 [1759012.001]
  • [Cites] J Surg Oncol. 1989 Feb;40(2):128-31 [2492623.001]
  • [Cites] Intern Med. 2007;46(14):1151-2 [17634719.001]
  • [Cites] Skeletal Radiol. 2003 Feb;32(2):107-10 [12589492.001]
  • [Cites] Pediatr Hematol Oncol. 2003 Jun;20(4):351-5 [12746169.001]
  • [Cites] Arch Orthop Trauma Surg. 2000;120(3-4):231-2 [10738893.001]
  • (PMID = 20205847.001).
  • [ISSN] 1757-1626
  • [Journal-full-title] Cases journal
  • [ISO-abbreviation] Cases J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2825505
  •  go-up   go-down


99. Farzaneh AH, Pardis PM: Central giant cell granuloma and fibrous dysplasia occurring in the same jaw. Med Oral Patol Oral Cir Bucal; 2005;10 Suppl 2:E130-2
Genetic Alliance. consumer health - Fibrous Dysplasia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Central giant cell granuloma and fibrous dysplasia occurring in the same jaw.
  • Fibrous dysplasia (FD) is a developmental tumor like condition that is characterized by replacement of normal bone by an excessive proliferation of cellular fibrous connective tissue intermixed with irregular bony trabeculae.
  • Central giant cell granuloma (CGCG) is described as a benign lesion affecting the mandible and maxilla that consists of a massive fibrohistiocytic proliferation with numerous heavily hemosiderin-laden multinucleate-giant cells.
  • Our differential diagnosis was osteoma, osteoid osteoma and Fd.
  • The histological feature reveal Central giant cell granuloma fibrous dysplasia.
  • Central giant cell granuloma and fibrous dysplasia occurring in the same jaw is rarely reported in the literatures.
  • [MeSH-major] Fibrous Dysplasia, Monostotic / complications. Granuloma, Giant Cell / complications. Mandibular Diseases / pathology
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans. Osteoma / diagnosis. Osteoma, Osteoid / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15995572.001).
  • [ISSN] 1698-6946
  • [Journal-full-title] Medicina oral, patología oral y cirugía bucal
  • [ISO-abbreviation] Med Oral Patol Oral Cir Bucal
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


100. Dridi M, Annabi H, Ben Ghozlen R, Abdelkefi M, Trabelsi M: Giant cell tumour of a phalanx in the foot: a case report. Acta Orthop Belg; 2008 Apr;74(2):273-5
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant cell tumour of a phalanx in the foot: a case report.
  • Giant cell tumours are uncommon benign osseous neoplasias with an obscure origin.
  • The authors report a case of giant cell tumour involving a phalangeal bone in the foot and review the presentation, distinctive features and treatment of this tumour when occurring in this location.
  • A 28-year-old female patient was seen with an aggressive giant cell tumour of the first phalangeal bone of the third ray of her left foot.
  • En bloc resection of the third ray was performed without bone grafting.
  • When giant cell tumour occurs in such a location, it appears to represent a distinct, more aggressive form of tumour.
  • [MeSH-major] Bone Neoplasms / surgery. Giant Cell Tumor of Bone / surgery. Toe Phalanges

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18564489.001).
  • [ISSN] 0001-6462
  • [Journal-full-title] Acta orthopaedica Belgica
  • [ISO-abbreviation] Acta Orthop Belg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Belgium
  •  go-up   go-down






Advertisement